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Resumo 
A diabetes mellitus, ou simplesmente diabetes, pode ser definida como um conjunto complexo de 
perturbações crónicas de cariz metabólico caracterizadas por hiperglicémia. A diabetes tipo MODY, 
do inglês Maturity-onset diabetes of the young, é uma forma monogénica de diabetes. Inicialmente 
descrita em 1974 por Tattersall, a diabetes tipo MODY engloba um grupo de fenótipos heterogéneos, 
clinica e geneticamente, caracterizados por alterações no funcionamento normal das células beta do 
pâncreas e por um padrão de hereditariedade autossómico dominante. De uma forma geral, a diabetes 
tipo MODY tem um perfil não-insulino dependente e manifesta-se em crianças e indivíduos jovens, 
sendo tipicamente diagnosticada antes dos 25 anos. 
A diabetes tipo MODY aparenta ser rara, estimando-se que seja responsável por 0,6-2% dos casos de 
diabetes na Europa. No entanto, é frequente esta forma de diabetes ser equivocamente diagnosticada 
como diabetes tipo 1 ou tipo 2, pelo que a sua prevalência real deverá ser superior. Um dos grandes 
trunfos no combate a este subdiagnóstico da diabetes tipo MODY são os testes genéticos. Desde a 
década de 1990, foram 13 os genes associados à MODY. Mutações em heterozigotia nos genes GCK e 
HNF1A são as causas mais frequentes de diabetes tipo MODY, correspondendo a cerca de 70% dos 
casos. Logo a seguir estão as mutações em heterozigotia nos genes HNF4A (hepatocyte nuclear factor 
4 alpha) e HNF1B, que correspondem a cerca de 15% dos casos. 
O gene GCK, localizado no cromossoma 7 (7p13), codifica o enzima glicocinase (glucokinase - 
GCK), também conhecido como hexocinase IV. Este enzima monomérico possui três isoformas - a 
isoforma 1, presente nas células beta, e as 2 e 3, presentes no fígado - e, no interior das células, atua 
como um sensor do nível de glicose. Nos hepatócitos, este enzima intervém no desencadear da 
glicólise e glicogénese, enquanto facilita a exocitose de insulina nas células beta. A diabetes tipo 
MODY, subtipo GCK, resulta de mutações de perda de função em heterozigotia no gene GCK, 
diminuindo a atividade do enzima, e caracteriza-se por uma hiperglicémia moderada, assintomática e 
não progressiva que se manifesta desde o nascimento. Estas mutações acabam por diminuir a 
quantidade de glicogénio sintetizado e impedem a normal libertação de insulina, ao aumentar a 
concentração mínima de glicose necessária à sua secreção. 
O gene HNF1A, localizado no cromossoma 12 (12q24.31), codifica um fator de transcrição 
(hepatocyte nuclear factor 1 alpha - HNF1A) homodimérico. Este fator de transcrição possui três 
isoformas, A, B e C. As três estão presentes no fígado, rins, pâncreas e intestinos mas a primeira 
predomina no fígado, rins e pâncreas fetal, enquanto a isoforma B predomina no pâncreas adulto. O 
HNF1A integra uma complexa rede de fatores de transcrição, desempenhando um papel regulador na 
expressão de diversos genes durante o desenvolvimento embrionário. No fígado, o HNF1A regula a 
expressão de vários genes hepáticos, como o gene que codifica para a albumina. Nas células beta, 
intervém na expressão de insulina e na proliferação e morte celular. A diabetes tipo MODY, subtipo 
HNF1A, resulta de mutações em heterozigotia no gene HNF1A. Estas mutações podem ter diversos 
efeitos, reduzindo a secreção de insulina em resposta a glicose e aminoácidos, e alterando a expressão 
de genes envolvidos no transporte (GLUT2) e metabolismo de glicose, afetando processos como a 
glicólise, gluconeogénese e derivação de aminoácidos para o ciclo de Krebs. O subtipo HNF1A está 
associado a defeitos na proliferação das células beta e caracteriza-se por uma incapacidade progressiva 
na secreção de insulina, que não acompanha o aumento de glicose em circulação, dando origem a uma 
hiperglicémia mais grave que o subtipo GCK. 
O gene HNF1B, localizado no cromossoma 17 (17q12), codifica um fator de transcrição (hepatocyte 
nuclear factor 1beta - HNF1B) que atua como homodímero ou heterodímero, com HNF1A. O gene 
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HNF1B produz três isoformas - 1, 2 e 3 - e é expresso no timo, pulmão, rim, fígado, pâncreas, 
estômago, intestino e trato genital. Este fator de transcrição, que integra a mesma rede regulatória que 
HNF1A, actua no desenvolvimento embrionário do pâncreas e do rim. A diabetes tipo MODY, subtipo 
HNF1B, resulta de mutações em heterozigotia no gene HNF1B e em cerca de 50% dos casos 
caracteriza-se por uma combinação de resistência à insulina e disfunção das células beta, exibindo, à 
semelhança do subtipo HNF1A, uma incapacidade na secreção de insulina em resposta a 
concentrações crescentes de glicose. Mutações neste gene podem também resultar em anomalias extra 
pancreáticas e afetar tecidos como o trato genital ou o fígado, sendo quistos renais o fenómeno mais 
observado. 
Neste estudo, foram recolhidas informações clínicas acerca de 39 indivíduos, 24 probandos e 15 
familiares, através de questionários enviados por vários médicos de diferentes hospitais portugueses. 
Com base nestas informações, como glicémia em jejum, prova de tolerância à glicose oral e HbA1c, e 
no diagnóstico clínico de diabetes tipo MODY, foram-nos referenciados indivíduos com uma história 
familiar de diabetes que evidencie um padrão hereditário dominante; sem autoanticorpos pancreáticos; 
com início de sintomas antes dos 25 anos; e índice de massa corporal maioritariamente normal. Estes 
24 probandos foram estudados por sequenciação de Sanger para os genes GCK e HNF1A, tendo sido 
também efetuada a pesquisa de inserções e deleções através da técnica MLPA (Multiplex Ligation-
dependent Probe Amplification). 
Entre substituições pontuais e pequenas deleções, a sequenciação de Sanger detetou 46 variantes 
genéticas, 19 no gene GCK e 27 no gene HNF1A. Entre estas, seis podem ser classificadas como 
patogénicas ou provavelmente patogénicas, sendo quatro no gene GCK e duas no gene HNF1A. As 
variantes patogénicas ou provavelmente patogénicas detetadas no gene GCK foram c.364C>T 
(p.(Leu122Phe)), uma alteração missense no exão 4 que cosegrega com diabetes e está associada à 
diabetes tipo MODY; c.579+1_579+33del, uma deleção de 33 pares de base no intrão 5 que elimina 
um local de splicing e também está associada à diabetes tipo MODY; c.766G>A (p.Glu256Lys), uma 
alteração missense no exão 7 que induz alterações conformacionais no enzima GCK, reduzindo a sua 
capacidade de ligação à glicose e subsequente atividade catalítica; e, finalmente, c.1268T>A 
(p.(Phe423Tyr)), uma alteração missense no exão 10 que cosegrega com diabetes e está associada à 
diabetes tipo MODY. Estas variantes foram encontradas num total de quatro probandos e cinco 
familiares. No gene HNF1A, as variantes patogénicas detetadas foram c.814C>T (p.(Arg272Cys)), 
uma alteração missense no exão 4 que cosegrega com diabetes e impede o fator de transcrição HNF1A 
de se ligar ao DNA, perdendo assim a sua atividade reguladora na expressão genética; e c.872del 
(p.(Pro291Glnfs*51)), uma deleção também localizada no exão 4 que provoca uma alteração na grelha 
de leitura, cosegrega com diabetes e possivelmente resulta de um fenómeno de splippage aquando da 
replicação de DNA, prevendo-se que resulte numa proteína truncada. Estas variantes foram 
encontradas num total de três probandos e três familiares. 
A técnica MLPA foi aplicada na investigação de inserções e deleções em 17 probandos. Três destes 
probandos geraram resultados sem qualidade, sendo necessárias novas amostras para eventual 
repetição. Noutros 11 nenhuma inserção ou deleção foi detetada. Nos restantes três probandos foram 
detetadas duas deleções patogénicas: deleção em heterozigotia dos exões 5 a 8 do gene GCK (c.484-
?_1019+?del) num probando; e deleção em heterozigotia do gene HNF1B (c.1-?_1674+?del) em dois 
probandos. A deleção no gene GCK deverá produzir uma proteína não funcional para gerar o fenótipo 
MODY, subtipo GCK. No entanto, não foi encontrada qualquer informação sobre esta deleção ou o 
seu efeito na proteína, pelo que poderemos estar na presença de uma nova mutação. Quanto à deleção 
do gene HNF1B, estas são frequentes e existem várias fontes que apontam deleções completas do gene 
como patogénicas, que muitas vezes incluem outros genes na mesma região (17q12). Um dos 
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probandos aparenta não ter história familiar de diabetes e, sendo mutações de novo frequentes, é 
possível que estejamos na presença de uma. No entanto, não haviam amostras de familiares para fazer 
estudos de cosegregação nestes dois probandos. A hemizigotia provocada por esta deleção deve 
resultar em MODY, subtipo HNF1B, por haploinsuficiência. Nenhum destes dois probandos aparenta 
ter anomalias renais. 
No total, entre 24 probandos, este estudo identificou 10 indivíduos com MODY, cinco do subtipo 
GCK, três do subtipo HNF1A e dois do subtipo HNF1B, realçando assim a importância de um 
diagnóstico correto, com recurso a ferramentas de genética molecular, uma vez que estes indivíduos 
tinham diagnósticos de diabetes tipo 1 ou tipo 2. Dos restantes 14 probandos sem qualquer variante 
patogénica/provavelmente patogénica, foi detetada pelo menos uma variante associada a diabetes tipo 
2. A utilização destas técnicas no âmbito do diagnóstico genético permite estabelecer o diagnóstico 
correcto, com implicações para a terapêutica a administrar e qualidade de vida dos utentes dos serviços 
de saúde. 
Palavras-chave: Diabetes; MODY; GCK; HNF1A; HNF1B 
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Abstract 
Initially described by Tattersall in 1974, maturity-onset diabetes of the young (MODY) is a form of 
early onset monogenic diabetes characterized by clinically heterogeneous phenotypes with autosomal 
dominant inheritance that generally result in β-cell dysfunction. Often misdiagnosed, MODY accounts 
for 0.6-2% of diabetes cases in Europe and 13 genes have been implicated in this form of diabetes, 
with heterozygous mutations in GCK and HNF1A being the most common etiologies, followed by 
heterozygous mutations in HNF4A and HNF1B. 
Glucokinase (GCK) is a monomeric enzyme that acts as a cellular glucose sensor, playing a role in 
glycogenesis and glycolysis in hepatocytes, and in insulin release in β-cells. Heterozygous loss-of-
function mutations in GCK decrease enzymatic activity and result in GCK-MODY, characterized by 
asymptomatic mild stable hyperglycemia present from birth. HNF1A-MODY is associated with 
impaired β-cell proliferation and is characterized by a progressive insulin secretory defect, resulting in 
a more severe hyperglycemia. This form of MODY is caused by heterozygous mutations in HNF1A, a 
gene that codes hepatocyte nuclear factor 1 alpha, a homodimeric transcription factor that regulates 
gene expression in embryonic development and plays a role in insulin expression and β-cell 
proliferation and death. Hepatocyte nuclear factor 1 beta (HNF1B) is also a transcription factor that 
acts as a homodimer, or a heterodimer with HNF1A. HNF1B is part of the same regulatory network as 
HNF1A and regulates embryonic pancreatic development, also playing a role in nephron development. 
Heterozygous HNF1B mutations result in HNF1B-MODY, characterized by a combination of β-cell 
dysfunction and insulin resistance in approximately 50% of mutation carriers. Like in HNF1A-
MODY, insulin secretion is compromised as glucose concentrations rise. Renal cysts are common. 
Clinical data on 24 probands and 15 relatives was collected through questionnaires sent by physicians. 
Subjects with a clinical diagnosis of MODY - family history of diabetes consistent with dominant 
inheritance pattern, no pancreatic autoantibodies, onset before 25 years of age and typically lean - 
were referred to this study by physicians for genetic screening via Sanger sequencing (for GCK and 
HNF1A) and Multiplex Ligation-dependent Probe Amplification (MLPA). 
Between point substitutions and small deletions, Sanger sequencing detected 46 variants, 19 in GCK 
and 27 in HNF1A. Six of these were pathogenic or likely pathogenic, four in GCK and two in HNF1A. 
GCK pathogenic or likely pathogenic variants were c.364C>T (p.(Leu122Phe)), in exon 4; 
c.579+1_579+33del, in intron 5, abolishing the donor splice site; c.766G>A (p.Glu256Lys), in exon 7, 
which induces conformational changes, decreasing glucose binding and catalytic activity; and 
c.1268T>A (p.(Phe423Tyr)), in exon 10. These variants were detected in four probands and five 
relatives. HNF1A pathogenic variants were c.814C>T (p.(Arg272Cys)), which renders HNF1A unable 
to bind DNA and exert its transactivating activity; and c.872del (p.(Pro291Glnfs*51)), predicted to 
produce a truncated protein and likely the result of replication slippage. Both variants are located in 
exon 4. These variants were detected in three probands and three relatives. 
MLPA analysis detected two pathogenic deletions: a heterozygous GCK exons 5 through 8 deletion 
(c.484-?_1019+?del) in one proband; and a heterozygous HNF1B deletion (c.1-?_1674+?del) in two 
probands. The seemingly unreported heterozygous GCK exons 5 through 8 deletion, which should 
result in a null variant that decreases overall enzymatic activity, could be a novel mutation. 
Heterozygous HNF1B deletions should result in HNF1B-MODY via haploinsufficiency. One proband 
had no apparent family history but de novo mutations are frequent. Both probands had no apparent 
renal abnormalities. 
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Among 24 probands, this study identified a total of 10 MODY cases, with five being GCK-MODY, 
three being HNF1A-MODY and two being HNF1B-MODY. Of the remaining 14 probands without 
any detected pathogenic/likely pathogenic variants, 11 had at least one type 2 diabetes associated 
variant. Hence, this study highlights the importance of genetic diagnosis in patients with diabetic 
phenotypes consistent with MODY, as a correct diagnosis impacts patient treatment and quality of life. 
Key words: Diabetes; MODY; GCK; HNF1A; HNF1B 
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1. Introduction 
1.1 MODY 
Maturity-onset diabetes of the young (MODY) is a form of early onset monogenic diabetes (1). It was 
first described in 1974 by Tattersall, who reported on three families with seemingly dominantly 
inherited mild non-progressive diabetes diagnosed in their teen years or early twenties (2). Currently, 
MODY describes a group of clinically heterogeneous phenotypes of familial diabetes. This group is 
characterized by monogenic, dominantly inherited autosomal disorders that generally result in β-cell 
dysfunction. MODY is typically noninsulin-dependent, afflicting children and young adults. As such, 
its early onset usually leads to a diagnosis before individuals reach 25 years of age (3–5). MODY's 
heterogeneous clinical profiles result from varying features such as genetic etiology, age of onset, 
severity of hyperglycemia, extra pancreatic features and treatment modality (4,6). 
Though seemingly rare, MODY is the most common form of monogenic diabetes, accounting for an 
estimated 0.6-2% of all diabetes cases in Europe (4). However, since it is often misdiagnosed as type 1 
diabetes (T1DM) or type 2 diabetes (T2DM), actual prevalence should be higher, but no population-
based study has been done (3,5). One study found that only 6% of MODY patients were correctly 
identified clinically, with 36% misdiagnosed as T1DM and 51% as T2DM (7). Another study reported 
that 25% of subjects with a T2DM diagnosis before 30 years of age actually had MODY, suggesting 
the use of widened diagnostic testing criteria to bypass this situation (8). This might reflect physicians 
limited awareness of the condition or cost restrictions in genetic testing. Thus, one cannot understate 
the importance of a correct diagnosis, which enables physicians to predict the likely clinical course 
and possibly impacts patient treatment and overall quality of life, as well as the cost effectiveness of 
the treatment process (3,7). This is attainable through molecular genetic techniques such as direct 
sequencing, which can diagnose MODY with up to 100% sensitivity by identifying mutations in the 
gene responsible for the phenotype and defining the associated subtype (3,5,9). 
In the 1990s, advancements in molecular genetics allowed identification of some genes responsible for 
MODY (6). MODY's phenotypes result from heterozygous mutations in genes involved in β-cell 
development or insulin secretion. Up to 13 genes have been identified and researchers believe many 
more to be associated, as only 10% to 20% of MODY cases in Japan and China are attributed to 
known MODY genes (6). Accordingly, investigators are prompted to identify these genes and clarify 
their role in the pathogenesis of MODY. The 13 genes know to cause MODY are (5,6): 
 hepatocyte nuclear factor 4 alpha (HNF4A, * 600281), also known as MODY1; 
 glucokinase (GCK, * 138079), also known as MODY2; 
 hepatocyte nuclear factor 1 alpha (HNF1A, * 142410), also known as MODY3; 
 pancreatic and duodenal homeobox 1 (PDX1, * 600733), also known as MODY4; 
 hepatocyte nuclear factor 1 beta (HNF1B, * 189907), also known as MODY5; 
 neuronal differentiation 1 (NEUROD1, * 601724), also known as MODY6; 
 Kruppel like factor 11 (KLF11, * 603301), also known as MODY7; 
 carboxyl ester lipase (CEL, * 114840), also known as MODY8; 
 paired box 4 (PAX4, * 167413), also known as MODY9; 
 insulin (INS, * 176730), also known as MODY10;  
 B lymphocyte kinase (BLK, * 191305), also known as MODY11; 
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 ATP binding cassette subfamily C member 8 (ABCC8, * 600509), also known as MODY12; 
 potassium voltage-gated channel subfamily J member 11 (KCNJ11, * 600937), also known as 
MODY13. 
Mutations in GCK and HNF1A are by far the most common causes of MODY, accounting for nearly 
70% of cases (3). The relationship between the two varies according to geographical location, with 
GCK mutations being the most common in Spain, France, Italy (5), Germany, Austria (10), Japan (11) 
and the Czech Republic (12); and HNF1A mutations the most common in Denmark, the UK, the 
Netherlands (12), China (13) and Korea (14). This variation could be attributed to differences in 
screening strategies, as countries that seldom perform routine blood glucose tests have higher 
diagnostic rates for MODY3, as opposed to countries that routinely perform blood glucose tests, which 
present a higher prevalence of GCK mutations (3,5). Extending the focus to include HNF4A alongside 
GCK and HNF1A mutations, these three account for up to 80% of all cases (3,4). The fourth most 
common cause of MODY are HNF1B mutations, which comprise about 5% of cases (3,5). Each of the 
remaining nine genes is responsible for up to 1% of cases (5).  
Several types of mutation have been identified in GCK, HNF1A and HNF4A, including missense; 
nonsense; splicing; promoter region variants; frameshifts; small, partial and whole gene deletions; 
insertions and duplications (3,7,15,16). MODY mutations have a relatively high penetrance (4).  
1.2 Differentiating MODY from T1DM and T2DM 
Between 50% and 80% of MODY patients are diagnosed with T1DM or T2DM at presentation (5,12). 
Beyond physician's lack of awareness, due to MODY's rare occurrence, lies a problem posed by 
overlapping clinical signs between MODY and T1DM/T2DM (5). One study found that 82% of 
individuals with a molecular diagnosis of MODY first presented with polyuria and polydipsia, and 
44% with weight loss complaints, all classical signs of diabetes. The same study also noted that only 
half the MODY positive subjects had parental history of diabetes, with the same holding true for 
MODY negative subjects (7). 
Typical MODY diagnostic criteria include onset before 25 years of age, family history of diabetes and 
lack of insulin dependence, and though less than half of individuals meet these criteria, they have 
displayed high specificity (and low sensitivity) (5,8,17). However, performing genetic tests on any and 
all individuals, with no regard to specific criteria is not cost-effective and can lead to inappropriate 
results. So how do we distinguish MODY from T1DM and T2DM? One could argue that MODY and 
T1DM are easily differentiable based on absence or presence of β-cell autoimmunity, respectively. 
This is generally true, as highlighted by a UK study (18), but it is possible to find atypical features in 
MODY, like positive autoantibodies. In fact, one study found that 17% of MODY individuals and 
34% of T2DM individuals were positive for at least one β-cell autoantibody (10). 
T2DM poses yet another problem for MODY diagnosis as its increasing prevalence in youths 
complicates the distinction of MODY from early onset T2DM by hampering the age of onset and 
family history criteria's usefulness. Also, MODY patients are typically lean, as opposed to early onset 
T2DM individuals. However, the increasing prevalence of adolescent and young adult obesity means 
more MODY patients present with increased body mass index (BMI), which could confound the 
diagnostic process (5,8). 
Thus, genetic testing is essential for a correct diagnosis of MODY and its subtype. Downstream 
advantages include: 1) implementation of optimal treatment, which leads to improved quality of life 
and improved glycemic control, if an individual transfers from insulin therapy to oral treatment with 
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sulphonylurea (6,19); 2) estimation of patient prognosis; 3) prompt screening for other abnormalities 
associated with MODY gene mutations; 4) allow screening of proband relatives to ascertain their 
carrier status (3,5). For an in-depth comparison between MODY, T1DM and T2DM see table 6.1 in 
the supplementary material section. 
1.3 GCK and GCK-MODY 
GCK, also known as hexokinase IV or hexokinase D, is a product of the GCK gene, located on 
chromosome 7 (7p13). According to NCBI, GCK has 13 exons, nine transcript variants and generates 
three tissue-specific isoforms via alternative splicing. Transcript variant 1 is expressed in pancreatic β-
cells, as well as multiple other cells, and encodes isoform 1, with 465 amino acid residues. Transcript 
variants 2 and 3 are expressed in the liver and encode isoforms 2 and 3, the major and minor hepatic 
isoforms, with 466 and 464 amino acid residues, respectively. Transcript variant 1 possesses a specific 
first exon with an exclusive 5' UTR, generating a unique N-terminus in isoform 1. Transcript variants 
2 and 3 have a liver specific first exon, distinct from the one in transcript variant 1. Transcript variant 
3 has a second exon that is also liver specific, which is absent from transcript variant 2. Thus, the three 
isoforms are discernible through their overall distinct N-termini, being otherwise identical among 
them. 
GCK has two distinct promoters, separated by 30 kbp of genomic DNA, that modulate tissue-specific 
expression. The upstream neuroendocrine promoter and its adjacent exon prompt transcription in β-
cells, as well as enteroendocrine cells, like the intestinal K- (20) and L-cells (21), glucose-sensitive 
neurons and multiple other cells in diverse tissues. Conversely, the downstream liver promoter and its 
specific adjacent exon incite transcription exclusively in hepatocytes (22,23). These alternative 
promoters and their leader exons are at the basis of GCK isoforms' distinct N-termini. 
In the liver, GCK synthesis is induced by - and solely dependent on - insulin, thereby reflecting the 
organism's nutritive state, either fed or fasting, with correspondingly high and very low GCK 
concentrations. Unlike insulin, glucagon has the opposite effect, suppressing GCK expression. 
However, in β-cells, GCK is constitutively expressed, regardless of the body's nutritive state and, by 
extension, insulin levels (22).  
GCK is a monomeric protein with a small and large domain separated by a deep cleft, where the 
glucose binding site is located. This cleft is composed from small domain residues (Thr168 and 
Lys169), large domain residues (Glu256 and Glu290) and connecting region II residues (Asn204 and 
Asp205). GCK is allosterically regulated and seems to have three structural conformations and two 
catalytic cycles. Two conformations have been solved: a catalytically inactive super-open 
conformation, with low glucose affinity; and a catalytically active closed conformation, with high 
glucose affinity. Evidence suggests an intermediary active open conformation, with high glucose 
affinity, free of substrates and other products. The transition between the super-open conformation, 
where the glucose binding site is exposed to the solvent, and the open conformation corresponds to a 
slow catalytic cycle, due to its complex and time consuming molecular rearrangements. In contrast, 
due to its less complex reorganization, transition between open and closed conformations is fast and 
easily reversible, corresponding to a fast catalytic cycle (16,22,24). 
GCK plays an important role in glucose homeostasis. Due to its low affinity towards glucose and 
cooperative kinetics, it acts as a highly sensitive glucose sensor in cells (25). Because it is not 
inhibited by its product, GCK is able to continuously carry its activity (23). This enzyme catalyzes 
transfer of a phosphate from ATP to glucose, the first and rate limiting step of glucose metabolism, to 
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generate glucose-6-phosphate (G6P). GCK activity peaks with hyperglycemia, being directly 
proportional to ambient glucose concentration (4,16). In hepatocytes, at low glucose concentrations, 
GCK regulatory protein (GKRP) binds and allosterically inhibits GCK in the nucleus, which adopts 
the super-open conformation. A raise in glucose concentration favors GCK release from GKRP, 
allowing GCK-glucose binding, accompanied by conformational change to the closed form and its 
translocation to the cytoplasm, where it can catalyze glucose phosphorylation (16,22,25). G6P's 
increasing concentration via GCK action leads to an increase in glycogenesis, as well as glycolysis and 
glucose oxidation, contributing to postprandial glucose level regulation (22).  
In the β-cell, GCK facilitates insulin release. G6P generated by GCK undergoes glycolysis to produce 
pyruvate, which then enters the tricarboxylic acid (TCA) cycle to yield ATP. This raises the ATP/ADP 
ratio, closing ATP-sensitive potassium channels and depolarizing the plasma membrane. In turn, 
voltage-gated Ca
2+
 channels open, resulting in Ca
2+ 
influx and, ultimately, insulin exocytosis. Like in 
hepatocytes, GCK controls the phosphorylation step, the first in glucose metabolism. Initiation of this 
pathway results in glycolysis and glucose oxidation, effectively meaning the initial reaction, catalyzed 
by GCK, exerts a great amount of control over glucose's metabolic flux (22,25). 
Given GCK's role in glucose metabolism and insulin release, it is no surprise that GCK mutations can 
result in both hyper- and hypoglycemia (16). Heterozygous loss-of-function mutations lead to a 
decreased phosphorylation rate. In the liver, this decreases the amount of glycogen synthesized, 
hindering postprandial glucose regulation (26). In β-cells, insulin secretion regulation is impaired, as 
evidenced by a shift to the right in the glucose insulin secretion rate dose-response curve, an 
expression of a decrease in these cells' responsiveness to glucose (27). Although still under tight 
homeostatic control, this means the glycemic threshold for insulin release is set at a slightly higher 
concentration, when compared to healthy controls (4). The overall net result of these mutations is 
hyperglycemia. 
Although rare, homozygous loss-of-function mutations also lead to hyperglycemia. These mutations 
bring about total GCK deficiency that manifests itself in the form of permanent insulin-requiring 
diabetes with neonatal onset. This more severe phenotype can also result from compound 
heterozygous loss-of-function mutations and is known as permanent neonatal diabetes mellitus 
(PNDM) (16). In opposition, heterozygous gain-of-function mutations, which have been increasingly 
reported, shift GCK to the active conformation at lower glucose concentrations, resulting in 
hyperinsulinemic hypoglycemia (4,16,28). 
Over 600 different mutations have been identified scattered throughout the GCK gene (16). 
Remarkably, the heterozygous loss-of-function mutations all result in an identical phenotype, due to 
the compensatory action of the remaining wild type allele (4). This phenotype is known as GCK-
MODY or MODY2 and is characterized by asymptomatic mild stable hyperglycemia present from 
birth. Being asymptomatic and non-progressive, hyperglycemia often remains undetected and 
individuals are usually incidentally diagnosed during routine investigations. The same applies to these 
individuals' relatives, who might be unaware of their carrier status and remain undiagnosed or 
misdiagnosed. Often, one parent has mild hyperglycemia and family history of T2DM or gestational 
diabetes (GDM) is common (4,5). 
Notably, GCK-MODY individuals retain good homeostatic control over blood glucose, as evidenced 
by glucose levels' small increase at the 120 minute mark of an oral glucose tolerance test (OGTT). In 
fact, one study found that, at this mark, 95% of individuals display glucose levels below 83 mg/dL 
(4.61 mmol/L) (4,5). This, coupled with hyperglycemia's non-progressive nature, makes micro- and 
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macrovascular complications rare (4). Additionally, treatment with oral hypoglycemic agents (OHA) 
or insulin therapy may be ineffective in decreasing glycated hemoglobin (HbA1c), as administration of 
low dose exogenous insulin leads to a compensatory decrease in endogenous insulin secretion, 
meaning glucose remains unaltered and HbA1c values are near normal (3,4,29). 
In pregnant women, insulin therapy may be necessary to prevent consequences for the baby (6). If the 
baby does not inherit a heterozygous loss-of-function GCK mutation from its afflicted mother, it will 
be at risk of macrosomia, due to increased insulin secretion and insulin-stimulated growth secondary 
to maternal hyperglycemia. However, if the baby inherits the mutation from the father and the mother 
is unaffected, there will not be enough glucose to stimulate the appropriate insulin secretion for normal 
fetal growth and the baby will be born underweight. If both mother and baby carry mutations, the baby 
will have the necessary glucose to stimulate the proper insulin secretion for normal fetal growth and, 
thus, the mutations cancel each other and the baby is born with normal weight (3–5,30). 
In lean young adults, teens and children, the following features are usually indicative of GCK-MODY 
(see table 6.1 for additional information) (3,4): 
 Persistent fasting hyperglycemia on at least three separate occasions spanning months to years 
(fasting plasma glucose (FPG) 99-153 mg/dL or 5.5-8.5 mmol/L); 
 HbA1c near normal (typically under 7.5%); 
 OGTT increment (120 minute glucose – 0 minute glucose) under 54 mg/dL or 3.0 mmol/L; 
 Persistent fasting C-peptide production (stimulated serum C-peptide>200 ρmol/L); 
 Negative pancreatic autoantibodies; 
 One parent will generally have mild hyperglycemia (FPG 99-153 mg/dL or 5.5-8.5 mmol/L) 
unless in the presence of a de novo mutation. 
For pregnant women, the diagnostic criteria are (3): 
 Persistent fasting hyperglycemia before, during and after pregnancy (FPG 99-144 mg/dL or 
5.5-8.0 mmol/L); 
 At least one OGTT increment under 82.8 mg/dL or 4.6 mmol/L during or after pregnancy; 
 Absence of family history should not exclude GCK-MODY as one parent may have mild 
diabetes that remains undetected. 
1.4 HNF1A and HNF1A-MODY 
HNF1A is a transcription factor encoded by the HNF1A gene on chromosome 12 (12q24.31). HNF1A 
has 10 exons and generates multiple transcripts via alternative splicing, which encode three different 
isoforms (figure 1.1) (31,32). According to Uniprot, isoform A encodes the longest protein of the 
three, with 631 amino acid residues, while isoforms B and C encode shorter truncated versions. 
Isoform B has 572 amino acid residues and isoform C has 524 amino acid residues. All three isoforms 
are present in the liver, kidney, pancreas, isolated islets and intestines, but their expression patterns 
differ. Isoform A is predominant in the liver, kidney and fetal pancreas, while isoform B is the most 
abundant in the mature pancreas, where it seems to play a role in the continued maintenance of β-cell 
function. Thus, HNF1A expression differs in space and time, according not only to tissue but also with 
developmental stage. This differential expression pattern may reflect differences in function between 
isoforms, as isoform A is thought to have the lowest transactivation potential of the three, or reflect 
differential activation of downstream effectors (33). 
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HNF1A has three functional domains: a dimerization domain, a DNA-binding domain and a 
transactivation domain (figure 1.1). Located in the nucleus, HNF1A acts as a homodimer, the 
predominant form in liver and pancreas, and plays a regulatory role in the expression of several genes 
in multiple tissues during embryonic development. In the liver, HNF1A binds several liver-specific 
genes like albumin or fibrinogen's alpha and beta chains, and a total of at least 222 genes in 
hepatocytes (34). HNF1A also plays a role in regulating insulin expression (also binding the insulin 
receptor promoter) and in the development, proliferation and cell death in the mature β-cell. Unlike in 
GCK-MODY, HNF1A mutations do not seem to influence birth weight, as in utero β-cell function is 
normal, which also supports HNF1A's differential expression throughout an individual's life (4,5,34). 
HNF1A shows great allelic heterogeneity (31), with over 400 pathogenic variants reported, most of 
them in exons 2 and 4. One study found that missense mutations dominate, corresponding to 54.7% of 
reported mutations, followed by frameshifts at 21.7%, splice site mutations at 8.7%, promoter region 
mutations at 1.9% and partial or whole gene deletions at 1.2% (5,15). Another study found that most 
dimerization and DNA-binding domain mutations were missense (74%); and truncating mutations 
were predominant in the transactivation domain (62%). Some transactivation domain missense 
mutations may result in just a mild phenotype or not even result in diabetes at all. Truncating 
mutations tend to lead to similar phenotypes, most likely via nonsense-mediated decay (NMD), 
ultimately resulting in haploinsufficiency (5,15,31). 
Heterozygous HNF1A mutations cause HNF1A-MODY. These mutations are highly penetrant, with 
63% of carriers developing diabetes by 25 years of age and 96% by 55 years, but tend to display 
variable expressivity, as some individuals are normoglycemic while others are hyperglycemic. This 
could point to modifier gene involvement (4,31). As HNF1A is expressed in several tissues and 
directly or indirectly influences multiple gene expression, HNF1A mutations have a wide range of 
possible consequences. In humans, glucose- and amino acid-induced insulin secretion is impaired, 
which has been associated with defective islet-cell glycolytic flux and oxidative phosphorylation. To 
shed some light on the underlying processes of HNF1A-MODY, one study used knockout mouse 
pancreatic islets and hepatocytes and found evidence that HNF1A deficiency alters gene expression for 
proteins involved in glucose transport, like glucose transporter 2 (GLUT2), and glucose metabolism, 
like key mitochondrial enzymes. Additionally, the same study found that numerous genes with 
functions spanning from glycolysis to gluconeogenesis to amino acid derivation to the TCA cycle 
were downregulated. As glucose metabolism is affected, glucose-dependent gene expression in 
HNF1A deficient islets is also affected. β-cell proliferation was also demonstrated to be impaired (35). 
However, it should be noted that HNF gene expression profiles differ between humans, mouse and rat, 
especially for HNF1A (32), meaning conclusions from animal models should be carefully interpreted. 
HNF1A mutation location has been shown to influence age of onset, with mutations in exons 1-6 
associated with a lower age at onset than mutations in exons 8-10 (3). This happens because mutations 
in exons 1-6 affect isoforms A, B and C, having a potentially more severe phenotype, while mutations 
in exons 8-10 only affect isoform A, which is not the predominant isoform in the mature pancreas. 
One study found this genotype-phenotype relationship to only be true for missense mutations and 
unrelated to the protein's affected functional domain (33). However, another study found that patients 
with truncating mutations were, on average, diagnosed four years earlier than patients with missense 
mutations, reflecting the potentially more severe consequences of truncating mutations. The same 
study also found that individuals with dimerization and DNA-binding domain missense mutations 
were 10 years younger at onset than individuals with transactivation domain missense mutations. This 
could be due to whether one, two or three isoforms are affected or due to a particular position's 
importance within a domain in relation to its function (figure 1.1) (3,4,31). 
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Figure 1.1: HNF1A structure. Gene structure (A) and isoforms A, B and C structure (B). Numbered boxes correspond to 
exons and hatched boxes to incorporated intronic sequences. Numbers 1 to 631 correspond to amino acid residue positions. 
Adapted from (31,33). 
HNF1A-MODY is characterized by a progressive insulin secretory defect that leads to a more severe 
hyperglycemia than GCK-MODY. Interestingly, these individuals often present normal FPG, which 
might result from sufficient insulin secretory capacity in HNF1A-MODY's early stages coupled with 
relative insulin sensitivity and low BMI. As a result, normal glucose concentrations are achieved. In 
fact, it has been demonstrated that non-diabetic mutation carriers have normal insulin secretion at 
normal glucose concentrations (36). It has also been demonstrated that non-diabetic mutation carriers 
already present β-cell deficiency before onset of hyperglycemia, which could be delayed by normal or 
increased insulin sensitivity. This means that, in the early stage of diabetes, these individuals do not 
require exogenous insulin, as can happen later (4,5,37). Regardless, HNF1A-MODY's progressive 
nature has time on its side as hyperglycemia worsens and patients ultimately tend to display poor and 
deteriorating glycemic control, with vascular complications – micro and macro – ensuing as frequently 
as they do in T1DM and T2DM. This is supported by large OGTT increments and impaired insulin 
secretion rate with rising glucose concentrations (4,36). 
In addition to the aforementioned decreased β-cell proliferation, increased cell death through apoptosis 
has been proposed to explain the declining β-cell function behind HNF1A-MODY's progressive 
profile (4,5). Despite this, patients present normal glucose levels at birth and are generally lean, with 
diabetes onset typically occurring in adolescence or early adulthood, before the age of 25 years (4). 
These individuals are more likely to progress from a state of normal glucose tolerance to impaired 
glucose tolerance (IGT) and, finally, to diabetes. All of this is to be expected given HNF1A's 
regulatory actions in the mature β-cell. 
HNF1A is expressed outside the pancreas and these patients often present extra-pancreatic features. 
HNF1A plays a role in glucose reabsorption in the proximal renal tubules, by directly regulating 
sodium glucose cotransporter 2 (SGLT-2) expression (37). Loss-of-function HNF1A mutations hamper 
this process, resulting in decreased SGLT-2 expression and reduced renal glucose reabsorption, 
ultimately leading to glycosuria that manifests itself even before onset of hyperglycemia. In fact, 38% 
of non-diabetic mutations carriers were found to have glycosuria subsequent to an OGTT. In the early 
stage of HNF1A-MODY, OGTT will show a marked increase in glucose concentration (3). In 
comparison with GCK-MODY, these individuals present higher OGTT increments, with lower insulin 
concentrations throughout the test, illustrating their insulin secretion defect (4,36,37). 
Additionally, HNF1A-MODY patients tend to have elevated HDL, unlike in T1DM and T2DM, where 
HDL concentrations tend to be normal and low, respectively. Despite this, cardiovascular risk does not 
seem to decrease, as coronary heart disease incidence sits between T1DM and T2DM (4). 
Interestingly, in rare cases, liver adenomatosis occurs due to upregulated expression of proliferation 
and cell cycle regulatory genes secondary to somatic HNF1A biallelic loss-of-function (31,35). 
A 
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In typically lean diabetic individuals with onset before the age of 25 years and a family history of 
diabetes, the following features are normally indicative of HNF1A-MODY (3,4): 
 OGTT increment (120 minute glucose – 0 minute glucose) over 63 mg/dL or 3.5 mmol/L; 
 Absence of pancreatic autoantibodies; 
 Persistent fasting C-peptide production (stimulated serum C-peptide >200 ρmol/L); 
 Glycosuria at glucose levels under 180 mg/dL or 10 mmol/L; 
 Normal or elevated HDL levels (>1.3 mmol/L); 
 Marked sensitivity to the OHA sulphonylurea (with improving glycemic control). 
OGTT will have higher diagnostic rate for HNF1A-MODY than GCK-MODY, due to its often normal 
FPG and greater OGTT increment, reflecting its insulin secretory defect and resulting impaired 
homeostasis capacity. In contrast, GCK-MODY is more easily diagnosed with FPG alone, as fasting 
hyperglycemia is persistent and OGTT increment is lower, due to relatively conserved insulin 
response that translates into a more capable homeostatic capability (36). Naturally, the combined use 
of diversified diagnostic criteria yields the highest diagnostic rates. 
1.5 HNF4A and HNF4A-MODY 
HNF4A is a transcription factor encoded by the HNF4A gene, located in chromosome 20 (20q13.12). 
HNF4A has 13 exons, with four variants for exon 1 (1A, 1B, 1C and 1D) (figure 1.2), and two 
promoters. The P2 (pancreatic) promoter is 46 kb upstream of the P1 (hepatic) promoter, controlling 
expression in the pancreas, though it is also used in hepatocytes (38,39), and its transcripts contain 
exon 1D (40). The P1 promoter seems to drive expression in the liver, kidney and fetal pancreas, but 
not in the mature pancreas (39), and its transcripts contain exon 1A (40). However, there are 
conflicting reports, with one study reporting P1-driven expression in the pancreas (40). According to 
NCBI, HNF4A generates multiple transcripts to encode 10 different isoforms, 1 through 10. These 
isoforms differ either at their N-terminus, C-terminus or both, by using alternate up- or downstream 
start codons and alternate splice and polyadenylation sites. Isoforms 1-6 are expressed via the hepatic 
promoter, while isoforms 7-9 are expressed via the pancreatic promoter, with isoform 8 being the most 
expressed in adult pancreas (39). Isoforms 2 and 8 are the alternatively spliced versions of isoforms 1 
and 7, respectively (40). So, much like HNF1A, HNF4A is differentially expressed in space and time. 
Globally, HNF4A is expressed in the liver, where it is the most abundant DNA-binding protein; 
kidney; pancreas, where it controls approximately 11% of islet genes (41); and intestines. In the 
mature β-cell, HNF4A expression is negatively regulated by itself (39). 
Like HNF1A, HNF4A is located in the nucleus and acts as a homodimer to bind DNA. HNF4A is part 
of the same complex transcription factor network that includes HNF1A and modulates gene 
expression in multiple tissues during embryonic development, being undoubtedly important as 
knockout animals are not viable (4,33). However, it seems HNF4A acts in a much larger number of 
hepatocyte and β-cell genes than HNF1A, by directly binding almost half of actively transcribed genes 
(34). One of the genes regulated by HNF4A is none other than HNF1A, which in turn also regulates 
HNF4A expression. As this regulatory network is linked to several nutrient transport and metabolic 
pathways, and considering the HNF4A-HNF1A regulatory loop, a disruption in these or other points in 
the network can result in a pleiotropic effect due to inefficient execution of cellular genetic 
programming, ultimately reflected in cellular dysfunction (35). In the liver, HNF4A is crucial for 
hepatocyte morphological and functional differentiation, glycogen storage and generation of hepatic 
epithelium (42), while also regulating expression of genes involved in gluconeogenesis and lipid 
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metabolism (41). HNF4A also plays a role in pancreatic development, β-cell differentiation and 
function maintenance (39), and insulin secretion, by directly activating the INS promoter (40).  
 
Figure 1.2: HNF4A gene and isoform structures. A: alternate first exons (1A-1D) in light grey and remaining exons in 
dark grey. B: HNF4A isoforms' structural composition. Hatched boxes correspond to retained intronic sequences. In black, a 
10 amino acid residue insertion in exon 9. P1 - hepatic promoter; P2 - pancreatic promoter. Adapted from (39). 
Heterozygous HNF4A mutations cause HNF4A-MODY, which accounts for 3-10% of MODY cases, 
depending on the sources (4,5). These mutations can be located in the gene itself or its P2 promoter 
(39). HNF4A-MODY is characterized by a phenotype identical to that of HNF1A-MODY, with 
progressive β-cell dysfunction. However, HNF4A mutations have lower, yet variable, penetrance, as 
some individuals remain free of diabetes in their fourth decade (3,4). Penetrance varies with affected 
isoforms, as mutations affecting all isoforms show the highest penetrance (39). Over 100 mutations 
have been reported in HNF4A: 58.3% are missense mutations; 11.7% are frameshifts; 9.7% are 
nonsense mutations; 5.8% are splice site mutations; 5.8% are promoter region mutations; and 1.9% are 
partial and whole gene deletions. Although mutations are found throughout HNF4A, most of them are 
located in exons 7 and 8 (15). 
Unsurprisingly, HNF4A-MODY's progressive β-cell defect translates in failure to appropriately 
increase insulin secretion in response to rising glucose concentrations. Like in HNF1A-MODY, 
mutation position is correlated with age at diagnosis, which could be explained by the differential 
expression patterns of HNF4A's isoforms. Mutations in exons 2-8, which affect all isoforms, are 
associated with earlier diagnosis, as opposed to mutations in exons 9 and 10, which affect isoforms 1, 
2, 4, 5, 7 and 8, and are associated with later diagnosis. Mutations affecting P2-derived isoforms are 
associated with a later age at diagnosis. Mutation type and location within isoform structure do not 
seem to influence age at diagnosis (39). 
As phenotypes are very similar, HNF4A mutations should be screened for when clinical features are 
highly suggestive of HNF1A-MODY but no HNF1A mutations are found (3). However, unlike 
HNF1A-MODY, HNF4A mutations are frequently associated with fetal macrosomia, as offspring of 
an affected mother or father have 50-56% risk of being born with excess weight (3,4). Increased in 
utero insulin secretion is associated with increased birth weight. In the neonatal period, increased 
insulin secretion can lead to hyperinsulinemic hypoglycemia, presenting in the first week of life. This 
condition affects approximately 10% of mutation carriers and can be transient or prolonged, ultimately 
transitioning to diabetes, though it is not known how nor when (4,5,39). 
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Due to its multi-tissue expression pattern and wide action range, HNF4A mutations also have extra-
pancreatic effects like low HDL, low apolipoprotein levels (apo A1, apo A2
1
, apo CIII, apo B), low 
triglycerides and elevated LDL. Unlike HNF1A-MODY, HNF4A-MODY individuals do not present 
glycosuria. Thus, the following features are indicative of HNF4A-MODY (4,5): 
 OGTT increment (120 minute glucose – 0 minute glucose) over 63 mg/dL or 3.5 mmol/L; 
 Persistent fasting C-peptide production (stimulated serum C-peptide >200 ρmol/L); 
 Negative pancreatic autoantibodies; 
 Macrosomia and/or neonatal hyperinsulinemic hypoglycemia; 
 Low HDL, low triglycerides, elevated LDL and sensitivity to the OHA sulphonylurea. 
1.6 HNF1B and HNF1B-MODY 
HNF1B is a transcription factor encoded by the HNF1B gene, located in chromosome 17 (17q12). 
According to NCBI, HNF1B has 11 exons and generates three transcripts via alternative splicing to 
encode three isoforms. Isoform 1 is the longest, with isoforms 2 and 3 lacking an internal segment and 
differing in their C-terminus, respectively. Like HNF1A, HNF1B has a dimerization domain, a DNA-
binding domain and a transactivation domain (figure 1.3) (44). HNF1B is expressed in early stage 
embryonic development in the thymus, lung, kidney, liver, pancreas, bile ducts, stomach, intestines 
and genital tract, being vital for embryonic survival (4,44). 
Also located in the nucleus, HNF1B acts as a homodimer or heterodimer. When acting as a 
heterodimer, HNF1B is coupled with HNF1A, a likely reflection of their homology, which includes 
the homeodomain and dimerization domain (44). HNF1B and HNF1A are actually paralogs with 
known interchangeable functions in several contexts, with HNF1B occupying a subset of direct 
HNF1A target genes to assure normal expression (35). HNF1B also binds HNF4A's P2 promoter, 
adding another nexus in this transcription factor network that regulates embryonic gene expression 
(39). HNF1B plays a role in nephron development, regulates embryonic pancreatic development and 
regulates expression of several genes involved in cholesterol and sphingolipid metabolism (45). One 
study assigns HNF1B a role in hepatic insulin sensitivity control (46). Another study suggests HNF1B 
functions as a classic transcriptional activator and as a bookmarking factor that marks target genes for 
rapid transcriptional reactivation after mitotic silencing via chromatin condensation (47). 
Heterozygous HNF1B mutations result in HNF1B-MODY, which accounts for 1-5% of all MODY 
cases. Penetrance is highly variable, as age at diagnosis ranges from 0 to 61 years (4,5). Mutation 
carriers also present variable phenotypes, with a wide range of clinical features. In one case, opposing 
clinical features have been associated to the same mutation within the same family (44,48). This 
variability is likely due to HNF1B's connections within its regulatory network. Over 65 mutations have 
been reported and approximately 28% of individuals present with full allele deletion (4,5,49). 
Moreover, de novo mutations are frequent, comprising as much as half of cases, meaning family 
history may be absent (4). Loss-of-function, dominant-negative and gain-of-function mutations have 
all been reported, falling in the missense, nonsense, frameshift, insertion/deletion, and splice site 
categories (44). One study found that mutations were predominantly located throughout the DNA-
binding domain, mostly in exons 2 and 4, but rarely affected exon 3, which is entirely included in this 
domain. The same study and one other report that intron 2's donor splice site was a hot spot for 
mutation (44,49). This second study also found the majority of mutations to be confined to the first 
four exons, which encode the dimerization and DNA-binding domains, with exon 2 being the most 
                                                          
1 HNF4A plays a role in apo A2 transactivation (43). 
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affected. This region is critical for transcriptional activity, meaning mutations in this area will result in 
reduced target gene activation. No missense mutations were found in the transactivation domain (44). 
 
Figure 1.3: HNF1B structure. Genomic structure and domain design are similar to those of HNF1A. Exon count refers to 
transcript NM_000458. Adapted from (44). 
Unlike the other HNF MODY, in approximately 50% of HNF1B mutation carriers, diabetes results 
from a combination of β-cell dysfunction and insulin resistance. Overall pancreatic atrophy, pancreatic 
dysplasia and exocrine dysfunction are common. Another distinctive feature is absence of 
sulphonylurea sensitivity, with insulin treatment required at an early phase. In utero insulin secretion 
is reduced, resulting in significant birth weight decrease (800-900 g). Like in HNF1A- and HNF4A-
MODY, insulin secretion is compromised as glucose concentrations rise, though initially maintained at 
normal glucose concentrations. As such, microvascular complications are also frequent (4,5,44). 
As HNF1B is expressed in several tissues during embryonic development, HNF1B mutations can also 
result in extra-pancreatic abnormalities. The most afflicted organ is the kidney, usually affected by 
renal cysts and diabetes (RCAD) syndrome, though renal structure anomalies seem to precede and be 
more prevalent in relation to diabetes. In fact, diabetes is not an essential feature for HNF1B mutation 
identification. Renal cysts are the most common abnormality, though renal dysplasia and renal tract 
malformations, like horseshoe kidney, have been reported. Moreover, less than 6% of HNF1B-MODY 
patients have normal renal function and about half have end-stage renal failure. Genital tract 
anomalies, like vaginal aplasia or azoospermia, have also been reported, but penetrance is incomplete. 
Other associated anomalies are liver dysfunction and abnormal liver function tests, specially alanine 
aminotransferase (ALT) and gamma-glutamyl transferase (GGT); gallbladder dysfunction; 
hyperuricemia and resulting gout; and hypomagnesemia (4,5,44,49). Thus, the following features are 
indicative of HNF1B-MODY (4): 
 OGTT increment (120 minute glucose – 0 minute glucose) over 63 mg/dL or 3.5 mmol/L; 
 Persistent fasting C-peptide production (stimulated serum C-peptide >200 ρmol/L); 
 Negative pancreatic autoantibodies; 
 Elevated creatinine and uric acid secondary to compromised renal function; 
 Elevated liver enzymes and low magnesium. 
1.7 Rare types of MODY 
The aforementioned types of MODY account for the vast majority of cases. However, a few cases 
have different genetic etiologies. Mutations in PDX1 (5), NEUROD1 (4,5), KLF11 (5,50), CEL 
(4,5,51), PAX4 (5,52), INS (5), BLK (4,5,53), ABCC8 and KCNJ11 (4,5) have all been associated with 
MODY, each accounting for less than 1% of all cases (5). Additionally, some individuals with MODY 
have no identified mutations in these genes, having what is known as MODY X. 
This study's objective is to perform the molecular characterization of Portuguese patients with a 
clinical diagnosis of MODY through PCR amplification and Sanger sequencing of GCK and HNF1A, 
and through Multiplex Ligation-dependent Probe Amplification (MLPA) for copy number variation 
(CNV) detection. This work is part of the large study "Molecular characterization of MODY patients" 
and is, to our knowledge, the first of its kind in Portugal. 
12 
2. Materials and Methods 
2.1 Inclusion criteria 
Between September 2013 and December 2015, subjects who presented with clinical diagnosis of 
MODY and met the selection criteria provided in the study protocol and clinical questionnaires were 
enrolled. These criteria were based on best practice guidelines defined by the European Molecular 
Genetics Quality Network (3). All subjects had been diagnosed with diabetes at some point in their 
lives. Proband candidates were typically lean, with onset of diabetes before 25 years of age, a family 
history of diabetes consistent with a dominant inheritance pattern and no pancreatic autoantibodies. 
When possible, relatives were also enrolled. 
The questionnaires sought to collect data on the following parameters: sex; ethnicity; age; age at 
diagnosis; family history of diabetes and renal disease; presence of retinopathy, coronary disease, 
neuropathy and nephropathy; birth weight; BMI; FPG; OGTT; HbA1c; pancreatic autoantibodies; and 
treatment type (diet, OHA or insulin). 
2.2 DNA extraction 
Subject DNA was extracted from whole blood in ethylenediamine tetraacetic acid (EDTA) using the 
salting-out method, based on Lahiri and Nurnberger's publication (54). Samples were stored at 4ºC 
until further use. 
2.3 DNA quantification and quality screen 
Sample DNA concentration was assessed with NanoDrop 1000 Spectrophotometer V3.7. To ensure 
reproducible results, each sample was measured at least twice. To ensure minimum DNA quality, all 
samples ran on a 1% agarose gel (1.0 g agarose in 100 mL 1X TBE buffer) for 45 minutes at 90 volt. 
Samples were loaded with a mix consisting of 4.5 µL loading buffer (bromophenol blue + glycerol) 
and 4.5 µL bidestilled water. Sample volume was 1 µL. 
2.4 Primer design, checks and preparation 
Primers were designed on Primer3Plus (55), with defined target regions ideally encompassing 70 
(minimum 50) or more base pairs up- and downstream the coding regions. For promoter regions, 
forward primers were located a few hundred base pairs upstream the first exon (494 bp in GCK and 
469 bp in HNF1A), with the reverse primers ending a little over 100 bp into the corresponding first 
exon (104 bp in GCK; 117 bp in HNF1A). Thus, primers to amplify exonic and adjacent intronic 
regions, and promoter regions were designed based on reference sequences for GCK (NG_008847.1; 
NM_000162.3) and HNF1A (NG_011731.2; NM_000545.6). All primer binding sites were checked 
for SNP's using the online tool SNPCheck. At the time of design, all primer binding sites were SNP 
free. See supplementary material for primer sequences. 
In silico PCR was performed online on University of California Santa Cruz (UCSC) for all primer 
pairs. Predictions showed all primer pairs amplified the intended target regions. The online UCSC 
BLAST-like Alignment Tool (BLAT) was used on all defined PCR products (target and included 
regions) to ascertain sequence similarity against genomic target regions and ensure the predicted 
products were the ones intended. Manual double-checks on the genomic RefSeqs were also performed 
for the same purpose. 
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PCR primers were synthesized by Frilabo. Dehydrated primers were stored at 4°C until rehydration. 
All primers were rehydrated with sterile bidestilled water in laminar flow cabinets, to 100 µM (100 
ρmol/µL) stock solutions. Working solutions were made from stock solutions at 10 µM (10 ρmol/µL) 
for PCR (10 µL from primer stock solution + 90 µL sterile bidestilled water) in 1.5 mL Eppendorf 
tubes® and, from the latter, working solutions were made at 2 µM (2 ρmol/µL) for Sanger sequencing 
(20 µL from PCR working solution + 80 µL sterile bidestilled water) in 0.2 mL tubes. All stock and 
working primer solutions were stored at -20°C. 
2.5 PCR optimization 
All PCR reactions were optimized as follows: triplicates from two healthy samples were initially 
amplified for each fragment at 59°C, 60°C and 61°C annealing temperatures. If necessary, annealing 
temperature was adjusted 1ºC (up or down) until optimum or satisfactory amplification was achieved. 
After running agarose gels, optimum annealing temperatures were set for each fragment. 
2.6 PCR reactions 
All PCR reactions, for both optimization and fragment amplification, were performed on either a 
Biometra T3000 thermocycler, an Applied Biosystems 2720 Thermal Cycler or a GeneAmp® PCR 
System 9700. Bioline reagents were used (dNTP's, 10x NH4-based reaction buffer, 50 mM MgCl2 
solution, and BIOTAQ™ DNA Polymerase) and kept stored at -20ºC. Standard PCR master mix and 
cycling program are available in the supplementary material. When possible, DNA samples were used 
at 100 ng/µL. When their concentration was below 100 ng/µL, samples were used as they were. 
2.7 Agarose gel electrophoresis 
PCR products were subjected to electrophoresis in 1.5% gel, polymerized from 1.5 g SeaKem® LE 
Agarose in 100 mL 1X TBE buffer (diluted from UltraPure™ 10X TBE Buffer), and 2.0 µL SYBR® 
Safe DNA Gel Stain. Gel was submerged in 1X TBE buffer and wells were loaded with previously 
mixed 5.0 µL loading buffer (bromophenol blue + glycerol) and 5.0 µL PCR product. Thermo 
Scientific GeneRuler 100 bp DNA Ladder (SM0241), 100-1000 bp, was used to check amplicon size. 
Typically, each run was 50 minutes at 90 volt. Electrophoresis were performed in Bio-Rad submerged 
horizontal electrophoresis cells (Mini-Sub® Cell GT Cell, Wide Mini-Sub Cell GT Cell, Sub-Cell® 
GT Cell and Sub-Cell® Model 192 Cell) with Bio-Rad power supplies (PowerPac™ HC or 
PowerPac™ Basic). Agarose gels were analyzed under UV light, with Safe Imager™. 
2.8 PCR product purification and Sanger sequencing reaction 
PCR product purification was performed with ExoSAP-IT™ PCR Product Cleanup Reagent, 
following manufacturer protocol, on the same thermocyclers as PCR reactions. 
Purified PCR products were then sequenced using the BigDye® Terminator v1.1 Cycle Sequencing 
kit. These reactions were also performed on the same thermocyclers as PCR reactions and then 
sequenced on Applied Biosystems® 3130xl Genetic Analyzer. See supplementary material for internal 
sequencing mix and cycling program. 
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2.9 Sequence analysis and variant interpretation 
Chromatogram analysis was performed with the Staden Package software (Trev, Pregap4 and Gap4 
programs) by aligning all chromatograms for each fragment and comparing them against each other 
and the correspondent RefSeq. For Pregap4 module configuration, see supplementary material. 
Sequence variants were analyzed and interpreted by querying open online databases, namely NCBI's 
dbSNP, 1000Genomes Browser, PubMed and ClinVar; Human Gene Mutation Database (HGMD), 
Exome Variant Server (EVS) and Exome Aggregation Consortium (ExAC); and also by querying in 
silico predictive software such as MutationTaster (56), PolyPhen-2 (57) and PROVEAN/SIFT (58,59). 
Final classification followed American College of Medical Genetics and Genomics (ACMG) and 
Association for Molecular Pathology (AMP) recommendations (60). Variant nomenclature was 
checked with Mutalyzer (61). 
2.10 MLPA 
MLPA was performed to investigate the presence of CNV on samples with no detectable 
pathogenic/likely pathogenic sequence variants via Sanger sequencing. MLPA was performed on a 
Biometra T3000 thermocycler, following the MLPA® DNA Protocol version MDP-005, as 
recommended by MRC-Holland, and using the SALSA MLPA probemix P241-D2 MODY mix 1 
description version 20 (lot D2-0413). Results were analyzed with the Coffalyzer.Net software and 
interpreted by querying PubMed, ClinVar, dbVar and HGMD. Protocol, probemix description and 
software are available at www.mlpa.com (62). 
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3. Results 
3.1 Subjects under study 
3.1.1 Number of subjects, sex, ethnicity, age and age at diagnosis 
Study sample consisted of 39 individuals, including 24 probands and 15 relatives, spread across 24 
families. Seventeen out of 39 were males (43.59%) and 22 females (56.41%). Among the proband 
group, there were nine males (37.5%) and 15 females (62.5%), whilst eight out of 15 relatives were 
male (53.33%) and seven were female (46.67%). Overall, the study sample was predominantly 
Caucasian (92.31%), with only three non-Caucasian individuals (7.69%), all of African descent and all 
in the proband group. Proband age ranged from 9 to 57, with a mean of 23.92 ± 11.24 years; whilst in 
the relatives group, age ranged from 7 to 79, with a mean of 46.47 ± 19.21 years. Overall mean age 
was 32.59 ± 18.33 years. Proband group age at diagnosis ranged from 1 to 35 years and presented a 
mean of 16.87 ± 8.29 years. Three individuals were diagnosed at 29, 33 and 35 years and information 
was not available for one proband. Among relatives, information was not available for six individuals. 
In this group, age at diagnosis ranged from 9 to 62 years, with a mean of 33.33 ± 18.48 years. 
3.1.2 Family history of diabetes and renal disease 
Only two subjects (8.33%) in the proband group presented without apparent family history of diabetes, 
with the remaining 22 (91.67%) presenting a positive family history of diabetes. Family history of 
renal disease was also screened and was present in one (4.17%) subject's family. Data was not 
available for six of the 24 probands (25%). The remaining 17 (70.83%) had no apparent family history 
of renal disease. 
3.1.3 Vascular complications 
Subjects were screened for retinopathy, coronary disease, neuropathy and nephropathy. Out of 24 
probands, 22 (91.67%) had no retinopathy, coronary disease or neuropathy, with no data available for 
the remaining two. Only one individual (4.17%) had nephropathy and no information was available for 
one other individual. The remaining 22 were nephropathy free. Among relatives, data was scarce, 
available for three of the 15 subjects (20%) and none of them had vascular complications. 
3.1.4 Birth weight and BMI 
Gestation time ranged from 35 to 40 weeks and was overall normal, as only one individual, in the 
relatives group, was born before 38 weeks. Among probands, birth weight ranged from 1.90 to 4.00 
kg, with a mean of 3.16 ± 0.52 kg. Fourteen out of 24 probands (58.33%) were born with normal 
weight, between 2.50 and 3.99 kg; two (8.33%) were born macrosomic, at 4.00 kg or more; and just 
one (4.17%) was born below 2.50 kg. Data was not available for seven probands (29.17%). Among 
relatives, data was only available for two out of 15 (13.33%) subjects, one born with 3.00 kg and the 
other 4.10 kg. 
BMI was calculated before and at enrollment. In the proband group, before enrollment, BMI ranged 
from 13.3 to 34 kg/m
2
, with a mean of 22.10 ± 5.57 kg/m
2
. Eight subjects had normal BMI (33.33%), 
between 18.5 and 24.9 kg/m
2
; five (20.83%) presented BMI below 18.5 kg/m
2
; four (16.67%) were 
over 25 kg/m
2
; and no data was available for the remaining seven (29.17%). At enrollment, BMI 
ranged from 14.4 to 30.43 kg/m
2
, with a mean of 21.46 ± 3.88 kg/m
2
. Fourteen probands (58.33%) had 
normal BMI, five had low BMI (20.83%), three had high BMI (12.5%) and the remaining two had no 
available data (8.33%). Among relatives, BMI data before enrollment was not available. At 
enrollment, data was available for 10 out of 15 subjects (66.67%). BMI ranged from 18.5 to 35.3 
16 
kg/m
2
 with a mean of 24.62 ± 5.27 kg/m
2
. Five individuals had normal BMI (33.33%), five had high 
BMI and no subjects presented low BMI. 
3.1.5 FPG 
FPG was also measured before and at enrollment. Among probands, before enrollment, FPG ranged 
from 89 to 600 mg/dL, with a mean of 191.06 ± 138.09 mg/dL. Not considering two extreme values 
(468 and 600 mg/dL) mean FPG is 145.33 ± 46.14 mg/dL. Five (20.83%) subjects had FPG between 
100 and 125 mg/dL; 11 (45.83%) had FPG of 126 mg/dL or greater; and one (4.17%) had FPG below 
100 mg/dL. Data was not available for the remaining seven of 24 probands (29.17%). At enrollment, 
plasma glucose ranged from 78 to 279 mg/dL, with a mean of 130.94 ± 46.40 mg/dL. Seven (29.17%) 
subjects had plasma glucose between 100 and 125 mg/dL, but for one individual postprandial plasma 
glucose was measured, instead of FPG. Seven (29.17%) subjects had plasma glucose levels of 126 
mg/dL or above but, again, postprandial plasma glucose was measured for one individual. Two 
(8.33%) subjects had FPG under 100 mg/dL and the remaining eight (33.33%) had no available data. 
Among relatives, there was no data on FPG before enrollment. At enrollment, FPG ranged from 93 to 
144 mg/dL, with a mean of 118.17 ± 17.34 mg/dL. Seven (46.67%) subjects had FPG between 100 
and 125 mg/dL; three (20%) presented FPG of 126 mg/dL or above; two (13.33%) had FPG under 100 
mg/dL; and the remaining three (20%) had no available data. 
3.1.6 OGTT 
In the proband group, four out of 24 (16.67%) subjects had data on OGTT before enrollment. Two-
hour glucose ranged from 176 to 320 mg/dL, with a mean of 239.5 ± 66.46 mg/dL. Two (8.33%) 
subjects had two-hour glucose under 200 mg/dL, and the other two over 200 mg/dL. At enrollment, 
OGTT data was available for one individual (4.17%), who had a two-hour glucose of 160 mg/dL. 
There was no data on OGTT among relatives, before or at enrollment. 
3.1.7 HbA1c 
In the proband group, before enrollment, HbA1c ranged from 4.9% to 14.1%, with a mean of 7.56 ± 
2.38%. Twelve (50%) subjects had HbA1c of 6.5% or above, with seven (29.17%) between 6.5 and 
7.5%. Five (20.83%) subjects had HbA1c under 6.5% and the remaining seven (29.17%) had no data. 
At enrollment, HbA1c ranged from 5.1 to 12.4%, with a mean of 6.62 ± 1.87. Eight (33.33%) subjects 
had HbA1c of 6.5% or above, with five (20.83%) between 6.5 and 7.5%. Twelve (50%) subjects had 
HbA1c under 6.5% and the remaining four (16.67%) had no data. 
Among relatives, no data was accessible before enrollment. At enrollment, data was available for eight 
of 15 subjects (53.33%). HbA1c ranged from 5.5 to 7.2%, with a mean of 6.33 ± 0.58%. Three (20%) 
subjects had HbA1c between 6.5% and 7.5%. The other five (33.33%) presented values under 6.5%. 
3.1.8 Pancreatic autoantibodies 
Subjects were screened for glutamic acid decarboxylase antibodies (GADA) and islet cell antibodies 
(ICA) before enrollment. Data on pancreatic autoantibodies was available for 19 of 24 probands 
(79.17%), all negative for GADA and ICA. No information was available among relatives. 
3.1.9 Treatment type (diet, OHA and insulin) 
Data on diet therapy was available on 22 of 24 probands (91.67%). Nineteen (79.17%) probands were 
on diet and three (12.5%) were not. Among relatives, data was available for eight of 15 (53.33%) 
subjects. Two (13.33%) were on diet and six (40%) were not. 
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Data on OHA, among probands, was available on 21 of 24 (87.5%) subjects. Three (12.5%) were on 
OHA and 18 (75%) were not. In the relatives group, information was available on nine of 15 (60%) 
subjects. Seven (46.67%) were on OHA and two (13.33%) were not. 
Data on insulin therapy, among probands, was available for 23 of 24 (95.83%) subjects. Thirteen 
(54.17%) were on insulin and 10 (41.67%) were not. In the relatives group, data was available on nine 
of 15 (60%) subjects. Only two (13.33%) individuals were on insulin therapy. 
One (4.17%) proband and two (13.33%) relatives were on both diet and OHA. No proband or relative 
was on both OHA and insulin. Eleven (45.83%) probands were on both diet and insulin, but no subject 
among relatives was in the same situation. Only one (4.17%) proband was on all three treatment 
modalities at the same time, with no relative in the same situation. Two (8.33%) probands and one 
(6.67%) relative were not on any of the three treatment types. 
3.2 Molecular analysis: Sanger sequencing and MLPA 
We detected a total of 46 sequence variants via Sanger sequencing, six of them pathogenic or likely 
pathogenic (figure 3.1). Among GCK variants, 21.05% were pathogenic or likely pathogenic, versus 
just 7.41% in HNF1A. Two other sequence variants were detected by MLPA in GCK and HNF1B. 
 
Figure 3.1: Detected sequence variants. Number of GCK and HNF1A sequence variants found via Sanger sequencing. 
3.2.1 Sanger sequencing analysis: GCK 
We detected 19 sequence variants in 19 subjects, 14 probands and five relatives. Intron 8 was the most 
affected region, with five variants. No variants were found in exons 2, 3, 5, 6, 8 and 9 (figure 3.2). 
 
Figure 3.2: GCK sequence variants location. Distribution of GCK sequence variants throughout its genomic structure. 
Unsurprisingly, most variants were located in non-coding regions, with just three out of 19 (15.79%) 
in coding regions. The two most common variants, c.483+87A>C and c.679+38T>C, both present in 
11 probands, were located in introns 4 and 6, respectively. Conversely, all three coding region variants 
affected one proband each, as does a 33 bp deletion in the exon 5/intron 5 junction (figure 3.3). 
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Figure 3.3: GCK sequence variants and affected subjects. Number of subjects affected by each GCK sequence variant. 
Four of 19 variants can be classified as pathogenic or likely pathogenic for GCK-MODY. The first, a 
missense variant, is located in codon 122's first base (CTC>TTC), exon 4's first nucleotide. This 
c.364C>T (figure 3.4) variant is predicted to result in wild type hydrophobic leucine substitution by 
aromatic phenylalanine (p.(Leu122Phe)) and can be classified as likely pathogenic, as the nucleotide 
change occurs at a conserved position and is predicted to be deleterious by MutationTaster 
(0.999999982103552), PolyPhen-2 (1.000; 0.999) and PROVEAN/SIFT (-3.93/0.000). Additionally, 
c.364C>T cosegregates with diabetes, which is present in the proband's (III-2: 13-012) family (figure 
3.4), and is associated with MODY in HGMD (CM096822) and literature (16). To our knowledge, 
there is no population frequency data available for this variant. 
 
Figure 3.4: GCK c.364C>T proband chromatogram and pedigree. Proband chromatogram (top left), negative control 
(centre left), trace difference (bottom left) and pedigree (right). WD - without diagnosis. No data available for blank spaces. 
The next variant, c.579+1_579+33del, can be classified as pathogenic (figure 3.5). This 33 bp deletion 
in intron 5 abolishes the donor splice site. Proband (III-1: 15-010) phenotype is suggestive of GCK-
MODY, but cosegregation could not be ascertained as no relative samples were available. Though 
there is no population frequency data to our knowledge, this variant is associated with MODY in 
HGMD (CG942206) and has been previously reported as pathogenic (16,63). 
19 
 
Figure 3.5: GCK c.579+1_579+33del proband chromatogram and pedigree. Proband chromatogram (top left), negative 
control (centre left), trace difference (bottom left) and pedigree (right). ND - no data available. No data available for blank 
spaces. 
The third variant, c.766G>A (rs769268803) (figure 3.6), can also be classified as pathogenic. This 
exon 7 point substitution alters codon 256's first base (GAG>AAG), replacing the wild type aromatic 
glutamic acid with a basic lysine (p.Glu256Lys). Data on population frequency was only available on 
ExAC (MAF=0.00000824). This variant is classified as pathogenic on ClinVar and is associated with 
noninsulin-dependent diabetes on HGMD (CM930301). Additionally, this variant affects a conserved 
position and is predicted to be deleterious by MutationTaster (0.999999999995414), PolyPhen-2 
(1.000; 0.986) and PROVEAN/SIFT (-3.73/0.000). Proband (III-1: 15-019) phenotype is consistent 
with GCK-MODY, but cosegregation could not be ascertained, as relative samples were unavailable. 
The c.766G>A variant has been previously reported has pathogenic (16,64–66). 
 
Figure 3.6: GCK c.766G>A proband chromatogram and pedigree. Proband chromatogram (top left), negative control 
(centre left), trace difference (bottom left) and pedigree (right). No data available for blank spaces. 
The fourth and final variant, c.1268T>A (rs193922273) (figure 3.7), is also a missense variant 
(p.(Phe423Tyr)). This exon 10 point substitution alters codon 423's second nucleotide (TTC>TAC), 
changing the wild type aromatic phenylalanine to an also aromatic tyrosine. This variant can be 
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classified as likely pathogenic and is associated with MODY in HGMD (CM096954) and previous 
publications (16). The c.1268T>A variant affects a conserved position and is predicted to be 
deleterious by MutationTaster (0.999999544065252), PolyPhen-2 (0.998; 0.985) and SIFT (0.001). 
Proband (III-1: 15-011) and relative phenotypes are consistent with GCK-MODY, though c.1268T>A 
only cosegregates with diabetes in the proband's father. No population frequency data was available. 
 
Figure 3.7: GCK c.1268T>A proband chromatogram and pedigree. Proband chromatogram (top left), negative control 
(15-013) (centre left), trace difference (bottom left) and pedigree (right). NA - not applicable, ND - no data available. No data 
available for blank spaces. 
3.2.2 Sanger sequencing analysis: HNF1A 
We detected 27 HNF1A sequence variants in 23 subjects, 18 probands and five relatives. Exon 1 and 
intron 2 were the most affected regions, with four variants present in each. No variants were detected 
in the putative promoter region, 5' UTR, and exons 2, 3, 5, 6 and 10 (figure 3.8). 
 
Figure 3.8: HNF1A sequence variants location. Distribution of HNF1A sequence variants throughout its genomic structure. 
Again, most HNF1A variants were located in non-coding regions. However, coding region variants 
increased nearly three-fold, as 11 of 27 (40.74%) variants were located in coding regions. The two 
most common variants among probands, c.327-91G>A and c.1623+29T>C, were located in introns 1 
and 8, and present in 15 and 13 probands, respectively. The third and fourth most common variants, 
c.864G>C and c.51C>G, were located in coding regions - exons 4 and 1 - and were present in 11 and 
10 probands, respectively (figure 3.9). Furthermore, seven of the 11 (63.64%) coding region variants 
were located in exons 1 and 4, with the remaining four scattered through exons 7, 8 and 9 (figure 3.8). 
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Figure 3.9: HNF1A sequence variants and affected subjects. Number of subjects affected by each HNF1A variant. 
Two of 27 variants can be classified as pathogenic for HNF1A-MODY. The first, a missense variant, 
is located in exon 4. This point substitution in codon 272's first base (c.814C>T; CGC>TGC) (figure 
3.10) ultimately replaces the wild type basic arginine with a nucleophilic cysteine (p.(Arg272Cys)). 
This variant can be classified as pathogenic as the nucleotide change takes place at a conserved 
position and the amino acid substitution is considered radical by MutationTaster. Also, c.814C>T is 
predicted to be deleterious by MutationTaster (0.999999999948752), PolyPhen-2 (1.000; 0.988) and 
PROVEAN/SIFT (-6.30/0.001). Proband (14-014 and 14-015) phenotypes are consistent with 
HNF1A-MODY, though cosegregation could only be ascertained for 14-015's family (F30). In this 
family, c.814C>T cosegregates with diabetes in 14-015's mother (15-016) and brother (15-018) but the 
father (15-017) does not have this variant, despite being diabetic (figure 3.11). No relative samples 
were available regarding proband 14-014. The c.814C>T variant is associated with T2DM in HGMD 
(CM991168) and MODY in literature (67). No population frequency data was available. 
 
Figure 3.10: HNF1A c.814C>T proband (14-014) chromatogram and pedigree. Proband chromatogram (top left), 
negative control (centre left), trace difference (bottom left) and pedigree (right). Subject II-1 marked with "?" to represent 
he's unknown diabetes status, as he was going to draw blood for FPG evaluation. NA - not applicable, ND - no data available, 
BE - before enrollment, AE - at enrollment. No data available for blank spaces. 
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Figure 3.11: HNF1A c.814C>T proband (14-015) chromatogram and pedigree. Proband chromatogram (top left), 
negative control (15-017) (centre left), trace difference (bottom left) and pedigree (right). NA - not applicable, ND - no data 
available, BE - before enrollment, AE - at enrollment. No data available for blank spaces. 
Also in exon 4, we detected a frameshift that can be classified as pathogenic. This variant, c.872del 
(figure 3.12), abolishes codon 291's second nucleotide (CCA), shifting the reading frame 
(p.(Pro291Glnfs*51)). Though the affected position does not seem to be conserved, MutationTaster 
predicts c.872del to be deleterious with a probability of 1. Proband (IV-1: 13-005) phenotype is 
consistent with MODY and c.872del cosegregates with diabetes in the mother (14-017). The father 
(14-018) does not have the variant nor diabetes (figure 3.12). This variant is associated with MODY in 
HGMD (CD972460) and literature (68) but there is no apparent ClinVar entry. No population 
frequency data was found. 
 
Figure 3.12: HNF1A c.872del proband chromatogram and pedigree. Proband chromatogram (top left), negative control 
(bottom left) and pedigree (right). Subjects marked with "?" have unknown diabetes status. NA - not applicable, ND - no data 
available, BE - before enrollment, AE - at enrollment. No data available for blank spaces. 
In exon 9, a variant of uncertain significance was detected. This missense variant, c.1720G>A 
(rs1169305) (figure 3.13), affects codon 574's first nucleotide (GGC>AGC), replacing wild type small 
glycine with nucleophilic serine (p.(Gly574Ser)). Proband (III-2: 15-009) phenotype is consistent with 
diabetes but relative samples were not available for cosegregation study (figure 3.13). The c.1720G>A 
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variant is associated with T2DM in HGMD (CM020516). Proband is of African descent and data 
collected from the 1000 Genomes Browser points to a MAF of 0.05370000 in Africa and 0.0000 in 
Spain and Europe. According to Exome Variant Server, MAF in African-Americans is 0.038076. 
 
Figure 3.13: HNF1A c.1720G>A proband chromatogram and pedigree. Proband chromatogram (top left), negative 
control (centre left), trace difference (bottom left) and pedigree (right). Subjects marked with "?" have unknown diabetes 
status. NA - not applicable, ND - no data available, AE - at enrollment. No data available for blank spaces. 
Three other relatively common missense variants were detected, but all three can be classified as 
benign or likely benign, in accordance with their ClinVar entries. Two are located in exon 1 (c.79A>C 
and c.293C>T) and the other is located in exon 7 (c.1460G>A). The benign c.79A>C (ATC>CTC) 
variant (rs1169288) (figure 3.14) replaces isoleucine with leucine (p.(Ile27Leu)), both hydrophobic 
amino acids. Though at a conserved position, the change itself is conservative. MutationTaster 
(0.0042728067953222), PolyPhen-2 (0.025; 0.022) and PROVEAN/SIFT (-0.92/0.082) all predict this 
variant to be benign. Among probands, five subjects are heterozygous and one subject is homozygous 
for c.79A>C, a variant associated with insulin resistance in HGMD (CM001349) but not with β-cell 
function (69). MAF is over 0.05 in Spain (0.3224), Europe (0.33899999) and Africa (0.0832000). 
The same is true for European-Americans (0.335156) and African-Americans (0.120744). 
 
Figure 3.14: HNF1A c.79A>C proband chromatograms. Probands 15-008 (top left) and 15-009 (top right) chromatograms 
with respective negative controls (centre left and right) and trace differences (bottom left and right). 
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The likely benign c.293C>T (GCC>GTC) variant (rs1800574) (figure 3.15) replaces wild type small 
alanine with hydrophobic valine (p.(Ala98Val)), a moderately conservative change. Similarly, 
c.293C>T affects a conserved position, but MutationTaster (6.51464626319144e-06), PolyPhen-2 
(0.328; 0.141) and PROVEAN/SIFT (-2.23/0.063) predict it to be benign. This variant is present in 
proband 15-019 and is associated with reduced serum C-peptide and insulin responses to an OGTT in 
HGMD (CM971442) and literature (70). MAF is under 0.05 in Spain (0.0047), Europe (0.0278000) 
and Africa (0.0030000). This remains true for European-Americans (0.025671) and African-
Americans (0.004773). 
 
Figure 3.15: HNF1A c.293C>T and c.1460G>A proband chromatograms. Probands 15-019 (c.293C>T, top left) and 15-
003 (c.1460G>A, top right), respective negative controls (centre left and right) and trace differences (bottom left and right). 
The benign c.1460G>A (AGC>AAC) variant (rs2464196) (figure 3.15) replaces wild type 
nucleophilic serine for the amide asparagine (p.(Ser487Asn)), a conservative change. Again, 
c.1460G>A occurs at a conserved position, but MutationTaster (0.0158054424737475), PolyPhen-2 
(0.014; 0.085) and PROVEAN/SIFT (-0.61/0.111) predict this variant to be benign. Among probands, 
four subjects are heterozygous for c.1460G>A. This variant is associated with increased risk for 
cardiovascular disease in HGMD (CM067474) and literature (71). MAF is over 0.05 in Spain 
(0.3178), Europe (0.3161) and Africa (0.112). The same holds true for European-Americans 
(0.311163) and African-Americans (0.122787). 
3.2.3 MLPA analysis 
A total of 17 proband samples had no detectable pathogenic/likely pathogenic sequence variants via 
Sanger sequencing and were therefore tested for CNV's via MLPA. Three samples yielded low quality 
results, meaning new samples for these probands will be necessary to perform new MLPA runs. No 
CNV's were detected in 11 of the tested samples. Two major deletions were identified in the remaining 
three proband samples, namely a heterozygous deletion of GCK exons 5 through 8 (c.484-
?_1019+?del) in proband 15-014 (figure 3.16); and a heterozygous HNF1B deletion (c.1-?_1674+?del) 
in probands 13-006 and 14-013 (figure 3.17). Both deletions can be classified as pathogenic. 
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Figure 3.16: MLPA results for proband 15-014. Normalized fluorescence ratios are presented for all probes, including 
reference probes, with respective information regarding gene, exon and amplicon size. Area between blue and red lines 
corresponds to ratios between 0.7 and 1.3, indicating normal copy number. Ratios above 1.3 are indicative of duplication and 
ratios below 0.7 are indicative of deletion. Ratios between 1.3 and 1.65 are indicative of heterozygous duplication and ratios 
between 0.4 and 0.65 are indicative of heterozygous deletion. 
 
Figure 3.17: MLPA results for probands 13-006 (A) and 14-013 (B). Normalized fluorescence ratios are presented for all 
probes, including reference probes, with respective information regarding gene, exon and amplicon size. Area between blue 
and red lines corresponds to ratios between 0.7 and 1.3, indicating normal copy number. Ratios above 1.3 are indicative of 
duplication and ratios below 0.7 are indicative of deletion. Ratios between 1.3 and 1.65 are indicative of heterozygous 
duplication and ratios between 0.4 and 0.65 are indicative of heterozygous deletion. Ratios of zero are indicative of 
homozygous deletions. 
  
A 
B 
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4. Discussion 
Overall, the study sample complies with MODY's diagnostic criteria. Probands are typically diagnosed 
before 25 years of age, even though three probands were diagnosed up to 10 years later. Relatives are 
generally diagnosed later, which may reflect the presence of atypical T2DM phenotypes, incomplete 
penetrance, environmental/behavioral factors delaying diabetes onset or lack of awareness regarding 
MODY among healthcare providers, particularly a few decades ago. Additionally, most probands 
presented with documented family history of diabetes, elevated plasma glucose (>100 mg/dL), no 
pancreatic autoantibodies and normal or low BMI, as some subjects are children or teenagers. 
Interestingly, half the probands had normal HbA1c levels at enrollment and, though expected in 
HNF1A-MODY, vascular complications were not seen in these subjects, as the registered case of 
nephropathy was due to inherited polycystic kidney disease. This is most likely due to previous 
diagnosis and therapy implementation lowering circulating glucose and preventing future nefarious 
effects on the vascular system. In fact, most probands were on dietary therapy, insulin therapy, or 
both, and there is a clear reduction in both FPG and HbA1c from before study enrollment to the 
moment of enrollment, which occurs after healthcare intervention. 
Unfortunately, data on every indicator was not available for every subject, meaning study sample 
characterization could be skewed and, as such, should be interpreted with caution. Likewise, 
considering subjects were referred from multiple hospitals, clinical assessment may have varied with 
the observing physician, as some T2DM phenotypes might have been mistaken for MODY. 
In fact, some detected variants are associated with T2DM in HGMD and literature. The GCK 
c.1253+8C>T variant (rs2908274) in intron 9 was present in five probands - heterozygous in three, 
homozygous in two - and is associated with T2DM in HGMD (CS077759) and early onset T2DM in 
literature (72). However, this variant can be classified as benign for MODY and is considered 
polymorphic (i.e. benign) in literature (16). Also detected in GCK, the c.679+38T>C variant 
(rs2268574) in intron 6 is classified as benign (16), though it has been associated with GDM (73). 
In HNF1A, T2DM association is more prevalent, which is expected, given HNF1A's wider range of 
action. The previously mentioned c.79A>C, c.293C>T and c.1460G>A variants have been shown to 
decrease HNF1A's transcriptional activity upon GLUT2 (74) and have also been inconsistently 
associated with impaired glucose tolerance and/or an increased risk of T2DM (75). The c.79A>C 
variant is located in the dimerization domain, a highly conserved region of great functional 
significance (74), but does not seem to be associated with altered C-peptide and insulin release (70). 
However, it has been associated with insulin resistance, albeit via an unknown mechanism. 
Considering IGT is an insulin resistance state, the c.79A>C variant might be a risk factor or play a role 
in T2DM pathogenesis (69,76). It is also worth mentioning this variant is not associated with β-cell 
function (69). The c.79A>C variant is also associated with increased risk of subclinical coronary 
atherosclerosis and coronary heart disease, and with elevated LDL (71). 
The c.293C>T variant is much less frequent than the other two and, despite its likely benign 
classification, seems to be associated with reduced serum C-peptide and insulin responses to an oral 
glucose challenge (70). The c.79A>C and c.1460G>A variants have similar MAFs and have been 
shown to be in linkage disequilibrium (74). This should explain why the latter was also found to not be 
associated with altered C-peptide and insulin release (70). In addition to the T2DM link (77), and like 
the c.79A>C variant, the c.1460G>A variant has also been associated with increased cardiovascular 
disease risk and high LDL (71). The up- and downstream c.1375C>T (p.(=); rs2259820) and 
c.1501+7G>A (rs2464195) variants, in exon and intron 7, respectively, were also detected and show 
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very similar MAFs. The c.1375C>T variant is also associated with T2DM (77) and it would not be 
surprising if the intronic c.1501+7G>A variant shared this feature, as these three are likely in linkage 
disequilibrium. Furthermore, these three are classified as benign/likely benign in ClinVar. 
In intron 2, the relatively common c.527-51T>A (rs2071190) variant was detected in four subjects 
(one homozygous, three heterozygous) and is significantly associated with T2DM in both literature 
(78) and HGMD (CS066655). In exon 4, the also common c.864G>C (p.(=); rs56348580) variant was 
detected in a total of 16 subjects (eight homozygous, eight heterozygous) and, though classified as 
benign for MODY, it has been associated with T2DM in HGMD (CM067044) and literature (79). 
Most variants were located in non-coding regions. GCK variants seem scattered throughout the gene, 
as previously reported (16), with the exception of intron 8, which presented the greatest allelic 
diversity. In HNF1A, more than half of variants are located between exon 1 and intron 4, in agreement 
with previous reports (15,31). HNF1A variants comprised the majority of detected sequence variants, 
reflecting its great allelic heterogeneity (31). However, pathogenic or likely pathogenic variants for 
MODY were proportionately more common in GCK. 
Regarding these variants, in GCK, no additional information on c.364C>T was found. Absence of 
frequency data hints at a very low MAF, though this variant has been previously reported in two New 
Zealand families (16) and one Japanese family (80). The c.579+1_579+33del variant has been 
previously reported in three families, two French (16,63) and one Brazilian (81), and should equally 
have very low MAF, as there is seemingly no frequency data. This deletion likely results in a null 
variant, since both intron 5 donor splice site consensus bases (GT) are lost, but further RNA studies 
are necessary to understand the molecular consequences. The c.766G>A (p.Glu256Lys) variant has 
been previously reported in 11 families across Sweden, Spain and France (16,64,65), and seemingly 
decreases enzymatic activity. Glu256 is located in GCK's active site and, in its open form, is 
implicated in glucose binding by forming hydrogen-bond interactions with hydroxyls of bound 
glucose. Mutation to Lysine decreases maximal velocity (Vmax) with no significant change in Km for 
glucose, and should reduce glucose affinity by removing the hydrogen-bond (65). The Glu256Lys 
variant induces conformational changes in GCK's active site as well as the whole structure, resulting in 
decreased glucose binding and downstream loss of catalytic activity, thus explaining the 
hyperglicemic phenotype (66). Finally, the c.1268T>A variant may also have very low MAF, as no 
frequency data was found, though it was previously reported in multiple families (16), some in 
Portugal (82) and Brazil (83). 
In HNF1A, the c.814C>T variant has been previously reported in Japan (67), Italy (84) and Iceland 
(85). It is located in the DNA-binding domain and renders the protein unable to bind DNA, leading to 
a mutant with no transactivating activity. The resulting p.(Arg272Cys) protein acts in a dominant-
negative fashion, as HNF1A operates as a homodimer. The same study also reported a reduced insulin 
and glucagon secretory responses to arginine (67), highlighting α- and β-cell dysfunction. 
The c.872del variant is located in a transactivation domain proline rich region. This variant is 
predicted to lead to the synthesis of a truncated protein, due to an alternative termination codon arising 
51 codons downstream of the frameshift (p.(Pro291Glnfs*51)) (68). As the dimerization domain 
remains unchanged, it is possible this variant still forms a homodimer with the wild type protein, or 
with HNF1B, meaning it would act in a dominant-negative manner (85). It should be noted that 
frameshifts have been previously reported in the same position, one nucleotide downstream or one 
codon upstream, due to insertions (64), duplications (15,86) and deletions (85), respectively. This 
along with the fact that the wild type exonic region where these variants occur has eight C nucleotides 
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in tandem (figure 3.12) supports the hypothesis that this is a mutation hotspot resulting from 
replication slippage (85). Furthermore, subjects affected by the c.872del variant are homozygous for 
the benign but T2DM-associated c.864G>C, which adds another C nucleotide to this region. 
Finally, the c.1720G>A variant has been classified as both pathogenic and benign in ClinVar. Despite 
being very rare in Europe and associated with T2DM and atypical diabetes in African-American 
children (87), this variant occurs at a poorly conserved position, has a MAF over 5% in Africa and is 
predicted to be benign by PolyPhen-2 (0.002; 0.003) and PROVEAN/SIFT (-0.08/0.779). Given the 
subjects ancestry and conflicting data, it is not possible to conclude on this variant's pathogenicity. 
Of the six subjects (three probands and three relatives) with pathogenic HNF1A variants, four were on 
insulin therapy and one on OHA, underlining their poor glycemic control. As most of them were on 
therapy at enrollment, mean FPG was just mildly elevated (114.6 ± 17.26 mg/dL) and HbA1c was 
normal (5.94 ± 0.40%). Age at diagnosis was also lower for exon 4 pathogenic variant carriers versus 
exon 9 variant carriers, as expected (3), though the number of subjects is insufficient to reach solid 
conclusions. Age at diagnosis was unexpectedly higher in subjects with frameshift variants in 
comparison with missense variants (25 versus 20.33 ± 14.47 years) though, again, the number of 
subjects was insufficient to reach solid conclusions. 
Of the ten subjects (five probands and five relatives) with pathogenic/likely pathogenic GCK variants, 
three were on diet, three other on OHA and the remaining four were not on treatment or had no 
available data. With the correct diagnosis, and considering GCK-MODY individuals usually retain 
good homeostatic control over blood glucose, it might benefit these subjects to follow a dietary 
therapy and pursue an active lifestyle. These subjects were diagnosed at different stages of their lives, 
either in their youth (age 7 and 9 years), their teens (16 years), young adulthood (at 22 years) and 
adulthood (at 42 years), as expected in GCK-MODY (4). 
Regarding the MLPA results, the heterozygous GCK exons 5 through 8 deletion should result in a null 
variant, decreasing the phosphorylation rate which, duly compensated by the wild type allele, would 
generate the characteristic GCK-MODY phenotype (4,16), even though the breaking points are not 
known. There was little clinical information available on proband 15-014, who was diagnosed at 16 
years of age and presented with family history of diabetes though, at the time, relative samples were 
unavailable for cosegregation study. At enrollment, FPG was mildly elevated (126 mg/dL) and HbA1c 
was 5.9%, in line with typical GCK-MODY phenotype. There was no data on patient treatment, 
although it is likely this proband was put on a diet. Partial GCK deletions seem to be a rare cause of 
GCK-MODY (16) and there is seemingly no information concerning a deletion of exons 5 through 8 - 
and its effects at the protein level - in ClinVar, dbVar, HGMD and PubMed, meaning we could be in 
the presence of a novel pathogenic mutation. Also, considering the GCK c.766G>A (p.Glu256Lys) 
variant in exon 7 affects the active site, decreasing glucose binding and catalytic activity, it stands to 
reason this multiexon deletion would have at least similar consequences (24,66). 
Conversely, HNF1B deletions are frequent (4,11,88,89). There are several entries concerning MODY-
associated whole gene deletions among HGMD, ClinVar, dbVar and PubMed, with many of these 
deletions spanning other genes at 17q12. Heterozygous HNF1B deletion was detected in two probands 
but, as breaking points are unknown, it is possible more genes are affected by these deletions. In fact, 
HNF1B deletion has been reported as the same genetic disorder as 17q12 deletion (90). Proband 13-
006 has no apparent family history of diabetes. However, this could be a de novo mutation, as they are 
frequent (4). Unfortunately, relative samples were unavailable and cosegregation study was not done. 
In opposition, proband 14-013 has two diabetic grandparents, one maternal and the other paternal but, 
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again, relative samples were not available. Proband 13-006 has a history of extremely high FPG and 
HbA1c - 600 mg/dL and 14.1% around the time of diagnosis, but 78 mg/dL and 5.5% at enrollment - 
while 14-013 shows just mild hyperglicemia (120 mg/dL) and normal HbA1c (5.8%), before and at 
enrollment. Insulin resistance is typical of HNF1B-MODY and patients are often on insulin treatment 
at early stages (91). In this case, both probands were on diet and insulin therapy. Additionally, though 
it is not known if the deleted region is exactly the same in both probands, HNF1B-MODY phenotypes 
are notorious for their heterogeneity (91), even in cases with the same mutation (44,48). Amazingly, 
both probands had no record of any renal abnormalities or other abnormalities of any kind. Renal cysts 
are a typical HNF1B-MODY feature (44), though their absence has been reported (91,92). However, it 
is possible these and other abnormalities were not thoroughly screened for. 
These whole gene deletions are pathogenic for HNF1B-MODY, as evidenced by several HGMD 
entries (CG055897, CG094325 and CG106852) (88,89), and seem to result in disease via 
haploinsufficiency (93,94). Considering HNF1B typically acts as a homodimer, hemizygous 
individuals will most likely be unable to produce enough homodimers to assure wild type phenotype 
expression. 
In the particular case of proband 13-006, normalized fluorescence ratios for two probes call for further 
analysis. The 189 nucleotide reference probe ratio is below normal, seemingly indicating a 
heterozygous deletion of the corresponding region. However, copy number changes of reference 
probes are unlikely and this particular probe is located within, or close to, a very strong CpG island. 
This low ratio could result from CpG islands' high GC content, which would hinder sample 
denaturation and subsequent probe hybridisation, ligation and amplification, generating a false 
positive result. These denaturation problems would also explain the apparent homozygous deletion 
suggested by HNF1B-6 probe's ratio (figure 3.17 - A). Actually, poor sample denaturation can result in 
false positives even when ratios suggest the apparent deletion of adjacent genomic regions (62), such 
as the GCK exons 5 through 8 deletion. Another possibility would be the high GC content in the 
sequence adjacent to HNF1B-6 probe's ligation site. As for the three probands whose samples 
generated low quality results, new samples are need to retest. These three samples had low DNA 
concentration and/or fragmented DNA, which could explain the obtained results. 
Additionally, it should be noted the MLPA technique has several limitations. Mutations or 
polymorphisms present in sequences detected by MLPA probes can reduce relative fluorescence peak 
heights, even when not located at the exact ligation site between each probe's oligonucleotide pair, 
therefore generating false positives. Furthermore, MLPA is a sensitive technique and its performance 
relies on operator proficiency. As specified in the MLPA protocol and probemix description (62), 
changes in sample purity and quantities or experimental conditions can also affect peak height for 
some probes. As such, MLPA results need confirmation by other methods. Considering the reported 
deletions' breaking points are unknown, long range PCR would serve both purposes, confirming the 
reported results and clarifying the breaking points locations. 
In conclusion, 10 out of 24 probands were identified as carriers of pathogenic/likely pathogenic 
MODY variants: five with GCK-MODY, three with HNF1A-MODY and two with HNF1B-MODY. 
Of the remaining 14 probands without any detected pathogenic/likely pathogenic variants, 11 had at 
least one T2DM associated variant and six of the 11 had T2DM associated variants on GCK and 
HNF1A. Thus, this study highlights the need for comprehensive and documented patient evaluation, 
including genetic testing, as a correct diagnosis impacts patient treatment and quality of life. Future 
work should focus on improving the current status quo, further educating healthcare providers on 
MODY's characteristics and diagnosis, as well as the benefits of genetic screening in patient 
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management. Development, improvement and implementation of online tools, such as diagnostic 
algorithms (17), can also aid healthcare providers. Furthermore, it is necessary to reach more 
individuals within national territory, screen more MODY genes, and establish a control panel to 
improve variant ascertainment and create a representative report of MODY's prevalence and features 
in the Portuguese population. Functional studies to determine the biological consequences of different 
variants, at mRNA and protein levels, are essential to better understand the underlying processes of 
MODY's subtypes. The creation of dedicated units to screen and monitor target populations in defined 
geographical areas (north, centre, south, Azores and Madeira archipelagos) would help in establishing 
a national database with anamnesis, molecular genetic and biochemical information that would 
ultimately improve patient diagnosis and management. 
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6. Supplementary material 
6.1 Comparative analysis of MODY, T1DM and T2DM 
Table 6.1: Differentiating MODY from T1DM and T2DM. Multiparametric comparison between GCK-MODY, HNF1A-
MODY, HNF4A-MODY, HNF1B-MODY, T1DM and early onset T2DM. DKA: diabetic ketoacidosis. Adapted from (4–6). 
 T1DM 
Early onset 
T2DM 
GCK-
MODY 
HNF1A-MODY HNF4A-MODY 
HNF1B-
MODY 
Insulin 
dependency 
Yes No No No No No 
Insulin resistance Rare Common Rare Rare Rare Rare
2
 
Parental family 
history 
2-4% Typically Yes Yes Yes Yes 
Age of onset 
6 months to 
young adult 
Teen to 
young 
adult 
Birth 
Teen to young 
adult 
Teen to young 
adult 
Teen to 
young 
adult 
Polyuria/ 
polydipsia 
Common Variable Variable Variable Variable Variable 
Obesity 
Population 
frequency 
Yes 
Population 
frequency 
Population 
frequency 
Population 
frequency 
Population 
frequency 
Acanthosis 
nigricans 
No Yes No No No No 
DKA Common Rare Rare Rare Rare Rare 
Microvascular 
complications 
Common Common Rare Common Common Common 
Other features None None None 
Glycosuria 
Normal/elevated 
HDL 
Macrosomia 
Low HDL & 
triglycerides 
Elevated LDL 
Neonatal 
hyperinsulinemia 
Genital & 
renal 
anomalies 
Renal 
cysts 
Treatment Insulin 
Exercise 
OHA 
progressing 
to insulin 
Not 
needed or 
diet 
Sulphonylurea 
May progress to 
insulin 
Sulphonylurea 
May progress to 
insulin 
Insulin 
FPG (mmol/L) Often >7.1 Often >7.1 >5.5; mild Often <5.5 Often <5.5 Often<5.5 
OGTT increment 
(mmol/L) 
Typically 
>3.5 
Typically 
>3.5 
Typically 
<3.0 
Typically >3.5 Typically >3.5 
Typically 
>3.5 
Serum C-peptide 
(ρmol/L) 
<200 (>5 
years) 
500->1000 100-900 100-700 100-700 100-700 
Pancreatic 
autoantibodies 
80-90% (at 
diagnosis) 
1-20% 
<1% 
(same as 
controls) 
<1% (same as 
controls) 
<1% (same as 
controls) 
<1% 
(same as 
controls) 
Pathophysiology 
Autoimmune 
β-cell 
destruction 
Insulin 
resistance 
and/or 
relative β-
cell 
deficiency 
Glucose 
sensing 
defect in 
β-cell 
Insulin secretion 
defect in β-cell 
Insulin secretion 
defect in β-cell 
Insulin 
secretion 
defect in 
β-cell 
                                                          
2 About 50% HNF1B diabetic mutation carriers have β-cell dysfunction, relative to insulin secretion, and insulin resistance 
(4). 
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6.2 Online tools 
 Primer3Plus: http://www.bioinformatics.nl/cgi-bin/primer3plus/primer3plus.cgi 
 SNPCheck: https://secure.ngrl.org.uk/SNPCheck/snpcheck.htm 
 UCSC in silico PCR: https://genome.ucsc.edu/cgi-
bin/hgPcr?hgsid=586569735_R9ktENtkdSaprva4TQoaAauWGzM4 
 UCSC BLAT: https://genome.ucsc.edu/cgi-
bin/hgBlat?hgsid=586569735_R9ktENtkdSaprva4TQoaAauWGzM4&command=start 
 MutationTaster: http://www.mutationtaster.org/ 
 PolyPhen-2: http://genetics.bwh.harvard.edu/pph2/ 
 PROVEAN/SIFT: http://provean.jcvi.org/genome_submit_2.php 
6.3 Interpreting in silico mutation predictions 
MutationTaster gives "disease causing" or "polymorphism" (i.e. benign) predictions, coupled with a 
probability value. A value close to 1 indicates a high "security" prediction. Probability values under 
0.5 indicate the automatic prediction for a variant differs from the classification MutationTaster would 
have made
3
. PolyPhen-2 gives "benign", "possibly damaging" or "probably damaging" predictions, 
with the score scale going from 0 (benign) to 1 (probably damaging). PROVEAN gives "neutral" (> -
2.5) or "deleterious" (≤ -2.5) predictions; and SIFT gives "tolerated" (>0.05) or "damaging" (<0.05) 
predictions. 
6.4 Primer sequences, PCR master mix and cycling program 
6.4.1 Primer sequences 
Table 6.2: Primer data. Data on primer sequence, size (bp), annealing temperature (ºC), orientation (forward or reverse), 
amplicon size (bp) and genomic location. 
Primer sequence (5'-3') 
Size 
(bp) 
Annealing 
temperature 
(ºC) 
Primer 
type 
Amplicon 
size (bp) 
Genomic 
location 
Gene 
CCTGTCCAGCTTTGGACTCT 20 
62 
F 
598 Promoter 
GCK 
(MODY2) 
GTGACCTGGGGACAGCTTTT 20 R 
TGCATGGCAGCTCTAATGAC 20 
62 
F 
754 Exon 1 
CCTTCTCAAAGAGCCTGTGC 20 R 
GTGTGCAGATGCCTGGTG 18 
62 
F 
346 Exon 2 
CTGGCTGTGAGTCTGGGAGT 20 R 
CCTTCCCTCCTCCTCTTTGT 20 
61 
F 
364 Exon 3 
CCACCCCTGGTAGACAGGT 19 R 
CGGAAGAGGAGAGGGAAACT 20 
61; 62 
F 
382 Exon 4 
CCAGATCTCCCTTCTGAGCA 20 R 
CTGCTCTGAGCCTGTTTCCT 20 
62 
F 
565 Exons 5 and 6 
ACCAGGCTCTGCTCTGACAT 20 R 
CCATTGTTCCAGACAAAGCA 20 
60; 61 
F 
400 Exon 7 
CAAGCCCATTATCTGCAATG 20 R 
GACATTTCTAAAGCTCTGGCTCA 23 
60 
F 
698 Exon 8 
CATCCCTGCTCTTGGCATC 19 R 
                                                          
3 For more information see http://www.mutationtaster.org/info/FAQs.html 
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GCTCAGCGAGGGAAAGAG 18 
60; 61 
F 
482 Exon 9 
GGGGGACGAGAAGAGGACTA 20 R 
GTCCCCCTTGGCCTAGATT 19 
61; 62 
F 
698 Exon 10a4 
AGGTCTGGTCAAGCTGTTGG 20 R 
CTACAGGGAGGCCTGGTGTC 20 
61 
F 
585 Promoter 
HNF1A 
(MODY3) 
CGGCAGACACAAACCAAACT 20 R 
AGTCCCTTCGCTAAGCACAC 20 
59-61 
F 
671 Exon 1 
GGCTCGTTAGGAGCTGAGG 19 R 
CCCTGTGTCCTGGCATAAAT 20 
59-61 
F 
489 Exon 2 
TGTGTAATGGGGATGGTGAA 20 R 
GCATGTGTGCTGTGTGTTTG 20 
61 
F 
491 Exon 3 
GCCAGGCTAAGCCAATATCA 20 R 
CAGATCTGCCAGCCTCAAAC 20 
58 
F 
480 Exon 4 
CATGAATGGAATGGAACCAA 20 R 
GCCTAAGCAAACCAATGGAG 20 
61 
F 
655 Exons 5 and 6 
CTCTTCCAGCTCCTGGATTC 20 R 
CTCTGGGAAGGAGAGGTGGT 20 
60; 61 
F 
397 Exon 7 
GTCCCAGAGACACATGCAGA 20 R 
AGTCTTGAGGCCTGGGACTA 20 
59; 60; 63 
F 
558 Exons 8 and 9 
CTTCCTCACAGCAGCCCTA 19 R 
GGTGTGACTTTGGGGTTCC 19 
61 
F 
850 Exon 10a5 
CAGAGTAGCCACCCAGGAAA 20 R 
F: forward primer. R: reverse primer. 
6.4.2 PCR master mix and cycling program 
Table 6.3: Standard PCR mix and cycling program. Minor adjustments in annealing temperature, cycle number or MgCl2 
volume were made to optimize some fragments' amplification. Each PCR reaction required 1 µL DNA sample (typically at 
100 ng/µL) added to 24 µL master mix. 
Cycling program 
PCR Mix (for one reaction) 
Reagent Vol (µL): 1x 
Temperature (ºC) Time 
 
H20 14.625 
95 5 min 
 
dNTP's 4 
94 45 sec 
38 cycles 
Buffer 2.5 
Annealing 45 sec MgCl2 0.75 
72 60 sec F Primer 1 
72 7 min 
 
R Primer 1 
4 15 min/∞ 
 
DNA polymerase 0.125 
 
Total volume 24 
                                                          
4 Primer pair covers terminating coding region but does not cover the entire exon 10. 
5 Primer pair covers terminating coding region but does not cover the entire exon 10. 
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6.5 Sanger sequencing mix and cycling program 
Table 6.4: Sequencing mix and cycling program. Typical sequencing mix (right) and cycling program (left). BigDye 
volume was adjusted considering fragment size. 1 µL was used for fragments under 400 bp; 1.5 µL for fragments up to 500 
bp; and 2 µL for fragments above 500 bp. Purified PCR product volume was adjusted considering DNA sample 
concentration. For concentrations under 100 ng/µL, 2 µL purified PCR product were used; and above 100 ng/µL, 1 µL 
purified PCR product was used. 
Temperature (ºC) Time  Reagents Volume (µL) 
96 1 min  Sterile H2O 6 
96 10 sec 
25 cycles 
Primer (2 ρmol/µL) 1 
58 5 sec BigDye reaction mix 2 
55 4 min Purified PCR product 0.5-2 
4 ∞   
6.6 Sequence analysis and pregap module configuration 
Staden Package chromatogram analysis was done by aligning sequence files/chromatograms and, in 
Gap4, manually screening for variants against a reference sequence and other subjects' sequence 
files/chromatograms. Before this, Pregap4 was used to assemble sequence files into contigs, following 
these steps: 
1. Add desired sequence files to the list of files to process; 
 
2. Set Pregap4 module configuration as illustrated; 
 
3. Hit run to assemble contig; 
4. Open the created database in Gap4 to screen for variants as previously described. 
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6.7 Detected sequence variants 
Table 6.5: Detected sequence variants. All GCK, HNF1A and HNF1B detected sequence variants are listed below. MAF's taken from each sequence variant dbSNP entry regard European 
(EUR) and African (AFR) populations. 
GCK (NG_008847.1; NM_000162.3; NP_000153.1) 
dbSNP 
Alteration 
(genomic) 
Alteration 
(transcript) 
Location Alteration (protein) MAF (EUR) MAF (AFR) ACMG classification References 
rs35670475 g.4703C>T c.-768C>T 
Before 
promoter 
p.(=) A=0.06460001 A=0.00450000 Benign - 
rs12702070 g.4791A>G c.-680A>G 
Before 
promoter 
p.(=) C=0.06460001 C=0.00830000 Benign (16) 
rs1799884 g.4955G>A c.-516G>A 
Putative 
promoter 
p.(=) A=0.17790000 A=0.16410001 Benign (16,76,95) 
rs13306391 g.5387C>G c.-84C>G 5' UTR p.(=) G=0.06660000 G=0.06730000 Benign (16,96) 
- g.43349C>T c.364C>T Exon 4 p.(Leu122Phe) - - Likely pathogenic (16,80) 
rs115206967 g.43526A>T c.483+58A>T Intron 4 p.(=) A=0.00100000 A=0.21630001 Benign (16) 
rs2268573 g.43555A>C c.483+87A>C Intron 4 p.(=) A=0.48510000 A=0.20880000 Benign (16) 
- g.(43915_48326)del c.484-?_1019+?del Exons 5-8 p.(Gly162Argfs*118) - - Pathogenic - 
- g.44456_44488del c.579+1_579+33del Intron 5 p.(?) - - Pathogenic (16,63,81) 
rs2268574 g.44702T>C c.679+38T>C Intron 6 p.(=) T=0.48510000 T=0.22010000 Benign (16,73) 
rs2268575 g.44749A>G c.679+85A>G Intron 6 p.(=) G=0.19479999 G=0.16410001 Benign (97) 
rs769268803 g.46677G>A c.766G>A Exon 7 p.Glu256Lys - - Pathogenic (16,64–66) 
rs76323047 g.48068T>C c.1019+107T>C Intron 8 p.(=) G=0.11930000 G=0.05300000 Benign - 
rs887686 g.48135G>T c.1019+174G>T Intron 8 p.(=) T=0.29319999 T=0.02270000 Benign - 
rs887687 g.48218G>C c.1019+257G>C Intron 8 p.(=) C=0.29220000 C=0.03780000 Benign - 
rs5883890 g.48236del c.1019+275del Intron 8 p.(=) -=0.34489998 -= 0.12860000 Benign - 
rs2971680 g.48265G>C c.1019+304G>C Intron 8 p.(=) C=0.05770000 G=0.37590000 Benign - 
rs2908274 g.48935C>T c.1253+8C>T Intron 9 p.(=) T=0.17690000 C=0.27460000 Benign (16,72,98) 
rs193922273 g.49158T>A c.1268T>A Exon 10a p.(Phe423Tyr) - - Likely pathogenic (16) 
rs13306388 g.49620G>A c.*332G>A 3' UTR p.(=) A=0.26539999 A=0.02190000 Benign (98) 
HNF1A (NG_011731.2; NM_000545.6; NP_000536.5) 
dbSNP 
Alteration 
(genomic) 
Alteration 
(transcript) 
Location Alteration (protein) MAF (EUR) MAF (AFR) ACMG classification References 
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rs1169289 g.5074C>G c.51C>G Exon 1 p.(=) C=0.46919999 C=0.31690001 Benign - 
rs1169288 g.5102A>C c.79A>C Exon 1 p.(Ile27Leu) G=0.33899999 G=0.08320000 Benign (69,71,74–76) 
rs34056805 g.5299C>T c.276C>T Exon 1 p.(=) T=0.00000000 T=0.01210000 Likely benign - 
rs1800574 g.5316C>T c.293C>T Exon 1 p.(Ala98Val) T=0.02780000 T=0.00300000 Likely benign (70,75) 
rs1169293 g.14997G>A c.327-91G>A Intron 1 p.(=) G=0.08550000 G=0.21709999 Benign (99) 
rs1169294 g.15046G>A c.327-42G>A Intron 1 p.(=) A=0.33600000 A=0.14980000 Benign (100) 
rs12427353 g.15353G>C c.526+66G>C Intron 2 p.(=) C=0.20080000 C=0.01130000 Benign - 
rs1169300 g.19677G>A c.527-98G>A Intron 2 p.(=) A=0.31610000 A=0.11800000 Benign (101,102) 
rs2071190 g.19724T>A c.527-51T>A Intron 2 p.(=) A=0.23559999 A=0.23600000 Benign (78) 
rs1169301 g.19752C>T c.527-23C>T Intron 2 p.(=) T=0.31610000 T=0.11800000 Benign - 
- g.20519C>T c.814C>T Exon 4 p.(Arg272Cys) - - Pathogenic (67) 
rs56348580 g.20569G>C c.864G>C Exon 4 p.(=) C=0.30320001 C=0.17780000 Benign (79) 
- g.20577del c.872del Exon 4 p.(Pro291Glnfs*51) - - Pathogenic (11,68) 
rs55783344 g.20751C>T c.955+91C>T Intron 4 p.(=) T=0.02290000 T=0.00230000 Insufficient data - 
rs1169302 g.20754T>G c.955+94T>G Intron 4 p.(=) G=0.44530001 G=0.27160001 Benign - 
rs3751156 g.22754G>T c.1108-42G>T Intron 5 p.(=) A=0.02290000 A=0.00230000 Insufficient data - 
rs138835108 g.22769C>T c.1108-27C>T Intron 5 p.(=) T=0.00300000 T=0.00080000 Insufficient data - 
rs2259820 g.23794C>T c.1375C>T Exon 7 p.(=) A=0.31610000 A=0.10890000 Benign (77,103) 
rs2464196 g.23879G>A c.1460G>A Exon7 p.(Ser487Asn) T=0.31610000 T=0.11200000 Benign (71,74,77) 
rs2464195 g.23927G>A c.1501+7G>A Intron 7 p.(=) T=0.37770000 T=0.12629999 Benign (99) 
rs55834942 g.25566G>A c.1545G>A Exon 8 p.(=) A=0.19880000 A=0.01210000 Benign (104) 
rs1169304 g.25673T>C c.1623+29T>C Intron 8 p.(=) A=0.16600001 A=0.45989999 Benign (104,105) 
rs1169305 g.25834G>A c.1720G>A Exon 9 p.(Gly574Ser) T=0.00000000 T=0.05370000 Uncertain significance (87) 
rs76003406 g.25926C>T c.1768+44C>T Intron 9 p.(=) T=0.05570000 T=0.00150000 Benign - 
rs735396 g.27296T>C c.1769-24T>C Intron 9 p.(=) G=0.37770000 G=0.12629999 Benign (101,104) 
rs1169309 g.27644G>T c.*197G>T 3' UTR p.(=) T=0.37670001 T=0.12629999 Benign - 
rs1169310 g.27885G>A c.*438G>A 3' UTR p.(=) A=0.37770000 A=0.12629999 Benign (106–108) 
HNF1B (NG_013019.2; NM_000458.3; NP_000449.1) 
dbSNP 
Alteration 
(genomic) 
Alteration 
(transcript) 
Location Alteration (protein) MAF (EUR) MAF (AFR) ACMG classification References 
- - c.1-?_1674+?del Exons 1-9 p.(?) - - Pathogenic (11,88,89,91,92) 
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